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Abstract
Rho Guanine Nucleotide Exchange factor (RGNEF) is a 180 kDa protein which forms
pathological neuronal cytoplasmic inclusions in degenerating spinal motor neurons in
amyotrophic lateral sclerosis (ALS) and for which the gene (ARHGEF28) is mutated in a subset
of cases. Despite having previously been shown to localize to the nucleus and to undergo a
nuclear cytosolic shift in response to cellular injury, the mechanism of its nuclear import has yet
to be elucidated. Here we use site-directed mutagenesis with a combination of subcellular
fractionation and confocal microscopy to identify a functional nuclear localization signal (NLS)
within the Pleckstrin Homology (PH) domain of RGNEF. We show that the function of the NLS
is conserved both in full length RGNEF and when expressed as only the PH domain. This
advances the growing body of literature implicating dysfunction in the nuclear import and export
pathways as a feature of ALS pathology. Additionally, this is the first PH domain-embedded
NLS identified, despite the prevalence of PH domains in the human proteome and the similarities
in their consensus motifs.
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Chapter 1
1

Thesis Rationale / Hypothesis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease often resulting in death
within 5 years of symptom onset (1,2). Epidemiological research suggests ALS poses an
increasing risk to Canadian health services as the number of individuals reaching the average age
of symptom onset will double by 2026 (3). Currently, the only compound that is approved for
treatment of ALS that has been shown to alter disease course, Riluzole, extends patient survival
by approximately 3 months and the mechanism by which it slows disease pathology is still
unknown (4).

Approximately 10% of ALS cases are classified as familial ALS (fALS) and show typical
Mendelian inheritance (5). Forty percent of these are due to mutations in the gene chromosome 9
open reading frame 72 (C9orf72) (6). The mechanism by which C9orf72 mutations result in
disease pathology is still unknown though a growing body of research has implicated C9orf72
mutations in dysfunction in the nuclear transport pathways (7–9). Further evidence of nuclear
transport dysfunction in ALS comes from the fact that many ALS-related proteins show nuclear
depletion in ALS patient neurons.

The transport of large proteins in and out of the nucleus is a tightly controlled process (10). The
classical nuclear import pathway is the best described mechanism and accounts for
approximately 45% of protein import into the nucleus (11). It is distinguished from alternate
mechanisms of import based on its use of nuclear localization signals (NLS) that interact directly
with the transport receptor importin-α (12,13). A heterodimer forms between importin-α and
importin-β1 to facilitate import through the nuclear pore complex (NPC) (14,15). This process is
driven by the cycling of Ras-related Nuclear protein (Ran), which recycles the importin subunits
from the nucleus into the cytoplasm (16).
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Pleckstrin Homology (PH) domains are an invariable component of guanine exchange factors
(GEFs), along with the Dbl Homology (DH) domain. Named for the protein in which it was first
discovered, Diffuse B-Cell Lymphoma (Dbl), the DH domain performs catalytic exchange of
GDP for GTP. The PH domain is thought to contribute to GEF activity by localizing the protein
to substrate rich membranes (17). Although no PH domain has been shown to play a role in
nuclear import, the Split Pleckstrin Homology (sPH) domain (a domain with similar
characteristics) within the protein phosphoinositol 3-kinase enhancer (PIKE) has been shown to
contain a functional NLS (18).

Rho guanine nucleotide exchange factor (RGNEF) is a 180 kDa ALS-linked protein that has
been shown to localize to the nucleus in low levels (19). As an ALS-linked protein, it shares
many hallmark characteristics of proteins linked to ALS including ALS-specific mutations (20),
localization to neuronal cytoplasmic inclusions (NCIs) (21) and being a stability element for low
molecular weight neurofilament mRNA (NEFL mRNA) (19,22). To date, no NLS has been
identified within the protein sequence. RGNEF does however contain a PH domain, which has
classically been known to contribute to subcellular localization.

Given the canonical function of PH domains in GEF activity, I hypothesize that the PH domain
of RGNEF plays a role in its subcellular localization. Specifically, I hypothesize that it may
contain a NLS responsible for RGNEF nuclear import.

1.1 Background of ALS
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the
progressive loss of upper and lower motor neurons, often resulting in death within 5 years of
symptom onset (1,2). Early symptoms vary depending on the site of onset: individuals with limb
onset present with wasting or weakening of the distal muscles (hands or legs); individuals with
bulbar onset present first with slurred speech and dysphagia (1). With both forms of onset, death
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typically occurs as a result of respiratory failure within 5 years of symptom onset, though
individuals with bulbar onset have a lower median length survival (23,24).

There are three recognized variants of ALS: sporadic (sALS), familial (fALS) and the Western
Pacific or Guamanian variant. The latter is considered an example of an environmental trigger.
Amongst the Chamorro peoples of Guam and the Japanese inhabitants of the Kii Peninsula ALS
was hyperendemic with peak incidence rates between 1950 – 1954 (25), with a steady decline
thereafter (26). The etiology of the Guamanian variant is still unknown. One hypothesis suggests
that the high incidence of the disease observed in 1945 was the product of biomagnification of
the neurotoxin beta-methylamino L-alanine (BMAA) in traditional foodstuffs. (27). However,
further research on this topic has failed to show high levels of BMAA in Chamorro individuals
(28). A second hypothesis suggests that the decrease in cases of ALS is the product of
westernization of Guamanian Society and the influence of the United States on Guamanian foods
and lifestyle (26).

The remaining cases of ALS are defined as either sALS or fALS. Cases of fALS are
distinguished from sALS by genetic inheritance of the disease; sALS has no apparent family
linkage and individuals do not harbour an ALS-causative genetic mutation. This classical
classification system is being challenged, however, as ALS is increasingly described as a
complex disease with a spectrum of genetic susceptibility factors. It has been proposed that fALS
and sALS classifications represent gene effect size. Single genes with large affect sizes produce
cases that are classified as fALS: genetic linkage is easy to identify. Cases where one or more
genes contributes, each of which has a smaller affect size, are likely to present as sALS (23,29).
This is supported by evidence of apparent genetic correlation in approximately 8 – 10% of cases
of sALS. For example, relatives of individuals with apparent sALS have been shown to be at an
increased risk for ALS (30).

In Canada, a growing population of individuals reaching the age of symptom onset pose a high
burden for healthcare providers and medical systems. An epidemiological examination suggests
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that the number of Canadians over the age of 60 will double by 2026, significantly increasing the
number of individuals at risk of developing ALS (3). The only compound currently available for
the treatment of ALS that alters disease course, Riluzole, has only been shown to have limited
impact on patient survival (4). Greater research into the cause of the disease is still needed to
identify treatment targets and to improve patient outcome.

1.2 Neuropathology and the disease process of ALS
The neuropathology of ALS is characterized by significant loss of muscle with thinning of the
ventral spinal roots and atrophy of the spinal cord (31). The ventral and lateral corticospinal
tracts show prominent pallor and gliosis as a result of loss of descending supraspinal motor
neurons (1). At the microscopic level, key features of ALS include neuronal cytoplasmic
inclusions (NCIs), neuronal nuclear inclusions (NNIs) and glial inclusions.

The most common NCI, ubiquitinated inclusions, are circular or fibrillar skeins observed in the
perikarya of the motor neuron (32). They have been shown to contain ALS-related proteins
including TDP-43 (33), FUS (34), and RGNEF (21). Hyaline conglomerate inclusions, a second
type of NCI, occur in the perikarya of motor neurons (31,35) and are immunoreactive for
neurofilament proteins (NF) (31,36). NFs are obligate heteropolymers composed of three
subunits differentiated based on their molecular weight: low molecular weight neurofilament
(NFL), medium molecular weight (NFM) and high molecular weight (NFH) (37). A loss of the
normal stoichimetric balance of NF subunits is thought to be key to their recruitment to NCIs, in
particular NFL expression (38). Several RNA binding proteins implicated in ALS have been
shown to regulate NFL subunit expression (19,39).

A second form of inclusions, NNIs are more prevalent in cases of ALS with frontotemporal
dementia (FTD) than ALS alone. A 2004 case study of an individual with ALS showed
eosinophilic nuclear inclusions in pyramidial neurons of the motor cortex and hippocampus (40).
Work done using a larger population of individuals with a diagnosis of either ALS-alone, FTD-
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alone or ALS-FTD showed ubiquitin immunoreactive intraneuronal inclusions in one case of
ALS-FTD, though no cases with a diagnosis of ALS only. NNIs were shown in about half (7 of
15) FTD cases, supporting the hypothesis that ALS and FTD may represent a spectrum of
disorders (41).

Glial inclusions are another neuropathological marker supporting the hypothesis of ALS and
FTD as a spectrum of disorders. An examination of TDP-43 immunoreactive ubiquitin-positive
inclusions in the neostriatum showed glial inclusions in all cases of ALS-FTD and most (12 of
14) cases of ALS-alone (42). Work done examining FUS immunoreative inclusions showed that
glial inclusions are present in oligodendrocytes and are more common in late onset cases (43).

1.3 Nuclear transport dysfunction in ALS
1.3.1 Chromosome 9 open reading frame 72: a regulator of nuclear
transport
Mutations in Chromosome 9 open reading frame 72 (C9orf72) account for approximately 40%
of all fALS cases (44). The mutation is observed as a massive intronic hexanucleotide (GGGCC)
repeat expansion (6,45). While healthy individuals appear to have about 23 repeats, ALS patients
range between 600 to 2000 repeats (45,46). The expanded RNA undergoes an unconventional
form of translation, called repeat associated non-ATG-initiated translation. This gives rise to
three distinct dipeptide repeat proteins (DPRs) depending on the reading frame translated from
the RNA bearing the expanded repeats (47). Despite the prevalence of C9orf72 repeats in ALS
patients, the mechanism underlying its pathogenesis remains unknown.

Many ALS-associated proteins show nuclear-cytoplasmic mislocalization. One hypothesis for
how mutations in C9orf72 may contribute to ALS pathology is by causing dysfunction in the
nuclear transport system of motor neurons. Supporting data has been shown in human, yeast, and
drosophila. First, the expression of the DPRs of C9orf72 in cultured human astrocytes results in
altered splicing of Ran GTPase: DPR expression causes exon 2-skipping, resulting in the
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removal of the first 88 residues of the protein (9). Ran GTPase provides the energy necessary for
nuclear transport, including non-classical nuclear import (see section 1.4.2). As well, two
unbiased screens performed in yeast have shown that both karyopherins and effectors of Ranmediated nucleocytoplasmic transport are modifiers of C9orf72 toxicity (8). Finally, in a
Drosophila model of C9orf72, a targeted RNAi screen using a library of 121 RNAi lines – which
encoded nuclear pore complex proteins, importins, regulators of the RanGTP cycle, and arginine
methylases - identified 15 enhancers and 4 suppressors of eye phenotype. These included both
RCC1 and RanGAP, 2 importin-α subunits, importin-β1, karyopherin-β2, and PRMT1 (7). This
suggests that alterations in nuclear transport may be a key component of C9orf72-mediated
toxicity.

1.3.2 TAR DNA-binding protein of 43 kDa
TAR DNA-binding protein of 43 kDa (TDP43) has become a major protein of interest in ALS
since it was identified in 2006 as a core component of ubiquitinated aggregates in motor neurons
and glial cells in the vast majority of ALS cases (48,49). Mutations in the gene encoding TDP43, TAR DNA Binding Protein (TARDBP) are found in 4% of fALS cases (50). It had also been
shown to have a role in RNA splicing of the cystic fibrosis transmembrane conductance regulator
(CFTR) (51). In the context of ALS, TDP-43 has been implicated in multiple aspects of the
disease pathogenesis. Key to this thesis, nuclear depletion of TDP-43 is a hallmark of disease
pathology in ALS (52).

The N-terminal TDP-43 contains a NLS, which facilitates its nuclear localization via the
classical nuclear import pathway (discussed in greater detail in section 1.4.2) (53). In healthy
cells, TDP-43 is found predominantly in the nucleus (54,55). However, in motor neurons of
individuals with ALS, TDP-43 is localized predominantly to the cytoplasm (56). In the
cytoplasm, TDP-43 has been shown to be a major component of ubiquitinated aggregates in ALS
motor neurons (48,49).
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Although TDP-43 nuclear depletion appears to be linked to ALS pathology, none of the ALSrelated TDP-43 mutations are located within the NLS (57). Past research from our lab has shown
upregulation of TDP-43 expression with prominent cytosolic localization in axotomized mouse
motor neurons (58). This suggests that TDP-43 nuclear depletion may occur after motor neurons
have begun degeneration and are in a state of stress.

1.3.3 Heterogeneous nuclear ribonucleoprotein A1
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is another RNA-binding protein with
a link to ALS. It has been shown to shuttle mature mRNA through the nuclear pore complex and
to interact with the Drosha complex in miRNA biogenesis (59). The prion-like domain (PrLD) of
hnRNP A1 is thought to contribute to its role in RNA binding. A rare mutation found in ALS
patients in the PrLD of hnRNP A1 increases hnRNP A1’s localization to stress granules (60).
Stress conditions have been shown to induce the translocation of wild-type hnRNP A1 from the
nucleus to stress granules (61).

The mechanism by which hnRNP A1 achieves nuclear shuttling is unique for two reasons. The
first is that the N-terminal M9 domain of hnRNP A1 acts both as a nuclear import (62,63) and
nuclear export signal (64,65). The second is that the M9 domain is capable of binding two
transport receptors: both karyopherin-β2 (66) and karyopherin-β2B (67). This dual-binding
illustrates the important and necessary role that hnRNP A1 plays in mRNA nuclear export in
normal, healthy cells.

1.3.4 The FET Family of proteins
The FET family contains three member proteins, from which it gets its name: Fused in
sarcoma/translocated in liposarcoma, Ewing’s sarcoma protein, and TATA-binding protein
associated factor 2N. The FET family of proteins all localize predominantly to the nucleus and
show nuclear depletion in ALS motor neurons.
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Fused in sarcoma / translocated in liposarcoma
Fused in sarcoma/translocated in liposarcoma (FUS) has many similarities to TDP-43, including
ubiquitous expression and the ability to bind both DNA and RNA. It has been found to form
irreversible inclusions when cells are exposed to environmental stress (68). FUS-immunoreactive
skeins and aggregates have been found in ALS motor neurons (21,34). Nuclear import of FUS is
achieved by binding Karyopherin-β1 (68). Mutations in FUS occur in approximately 4% of
fALS cases (44). Of interest, those mutations which affect nuclear localization have been shown
to cause more severe disease phenotype (52).

Ewing’s sarcoma protein
Another member of the FET family, Ewing’s sarcoma protein (EWS) is normally localized to the
nucleus and functions in RNA regulation (69). Mutational screening of ALS patients has shown
three missense variants of the gene encoding EWS (EWSR1). These variants affect EWS
localization (70). Post-mortem analysis of individuals with sporadic ALS have shown
redistribution of EWS to the cytoplasm (71). The C-terminal of EWS contains a PY-NLS
(discussed in section 1.4.3; 73,74). Its localization may be regulated by post-translational
modification: phosphorylation of a single tyrosine residue adjacent to the PY-NLS has been
shown to be necessary for karyopherin-β2 binding (73).

TATA-binding protein associated factor 2N
The third member of the FET family, TATA-binding protein associated factor 2N (TAF15), has
also been identified as having missense variants occurring in ALS patients (74). Like the other
members of the FET family, it is predominantly localized to the nucleus in healthy cells. When
mislocalized to the cytoplasm, it is found in stress granules (70,74). A NLS has been identified in
the C-terminal region of TAF15 (75). Methylation of the C-terminal region by protein arginine
N-methyltransferase 1 (PRMT1) of TAF15 is required for proper nuclear localization (76). The
observation that PRMT1 expression is affected by mutations in C9orf72 (7) raises the possibility
that mutations in C9orf72 may cause nuclear depletion of TAF15 by regulating PRMT1
expression.
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1.4 Nuclear transport
The preceding sections suggest that disruptions in nuclear transport may be a critical component
of ALS pathogenesis. The entry and exit of large macromolecules in and out of the nucleus is a
tightly regulated process. Like the plasma membrane, the nuclear envelope is an impermeable
barrier consisting of an inner and outer membrane. Movement through the nuclear envelope
occurs only through specialized pores, which are gated by large complexes of proteins termed
nuclear pore complexes (NPCs) (10). Figure 1 illustrates the NPC. A NPC is a large
supramolecular assembly composed of approximately 30 different proteins, termed nucleoporins
(NUPs). The total molecular weight of the complex is approximately 125 MDa, of which
approximately 55 MDa consists of the luminal domain embedded in the nuclear envelope.

Approximately 32 MDa of the complex consists of the cytoplasmic ring moiety, from which
eight long (approximately 50 nm), kinky cytoplasmic filaments emanate (77,78). Though at its
narrowest point the central pore is 45 – 50 nm in diameter, large proteins require active transport
in order to pass through the NPC (79,80). The mechanism by which larger molecules are
excluded from the nucleus is still unknown but may involve the nucleoplasmic basket (15).
Although the exact mechanism whereby nuclear transport receptors facilitate import of large
cargo proteins has not been determined, the interaction of transport receptors with NUPs
composing the cytoplasmic filaments – specifically those rich in FG repeats – is necessary for
the NPC conformational change required for import (81–83). A more thorough discussion on the
role of transport receptors will be offered below (Section 1.4.2).

10

Figure 1: The nuclear pore complex. The nuclear pore complex (NPC) is a supramolecular
structure of ~125MDa that spans the nuclear envelope. Small molecules are able to diffuse
through the central pore. Larger molecules require transport receptors in order to pass through.
The transport receptor importin-β1 is able to interact with Nucleoporins (NUPs) on the
cytoplasmic filaments to initiate a conformational change in the NPC that allows for the import
of it and its cargo. It is unclear what conformational changes are necessary as the central pore
should be large enough (~50nm) to accommodate some large proteins. It is theorized that the
nucleoplasmic basket may act to gate large molecules entering.
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Though it is widely agreed that larger molecules require targeting signals to translocate, the
literature still has not reached a consensus on the maximum molecular weight of a protein
allowing for its passive diffusion into and out of the nucleus. Both 40 kDa (84,85) and 60 kDa
(86–88) thresholds are often used in the literature. Others have suggested that this threshold may
be as high as 110 kDa (89). Despite the dispute in threshold, we can say definitely that molecules
greater than 110 kDa require active transport to enter the nucleus.

1.4.1 Nomenclature
For clarity, it is important to address nomenclature related to nuclear transport receptors.
Karyopherin is a term that was first used in 1995 to describe all transport receptors relating to
movement across the nuclear envelope, including the proteins responsible for nuclear export
(90). The karyopherin-β family of protein contains ten subunits involved in nuclear transport
(91). Importin-β1 is the first member of this family and is involved in classical nuclear import as
described in section 1.4.2. The remaining members of the karyopherin-β family participate in
alternate forms of nuclear transport. The names of some of these protein and the ALS-linked
proteins they interact with are shown in Table 1.

1.4.2 Classical nuclear import
Classical nuclear import describes a mechanism whereby cargo proteins form a complex with
both importin-α and importin-β1 subunits in order to translocate into the nucleus. It differs from
other mechanisms of nuclear import in that it is the only one where the cargo protein binds
importin-α. Its name harkens to the fact that it was the first identified mechanism of nuclear
transport, having first been described in 1984 (12,13). Classical nuclear import is estimated to
account for approximately 45% of import into the nucleus (11). Figure 2 illustrates the
mechanism of classical nuclear import, which is discussed below.
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Table 1: The members of the karyopherin-β family involved in nuclear import of ALSrelated proteins
ALS-related proteins that use this receptor for

Name

Alternate Name

Importin-β1

Karyopherin-β1

TDP-43

Karyopherin-β2

Transportin-1

FUS, EWS, hnRNP A1

Karyopherin-β2B

Transportin-2

hnRNP A1

nuclear localization
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Figure 2: The classical nuclear import pathway. The classical nuclear import pathway is characterized by the interaction of a cargo
protein with the importin-α – importin-β1 heterodimer. Importin-α (red) initially forms a heterodimer with importin-β1 (blue) through
an importin-β binding domain (IBB). The cargo protein (green) can then bind importin-α directly via interaction of its NLS with the
NLS-binding domain of importin-α Interaction between importin-β1 and NUPs of the NPC (yellow) allows for the import of the
importin-cargo complex. The nucleus contains a high concentration of RanGTP, which binds importin-β1 and reduces its affinity for
interacting with importin-α. This causes the importin-cargo complex to dissociate, releasing the cargo protein into the nucleus.
Importin-α and importin-β1 are then able to exit the nucleus via the NPC. The concentration of RanGTP is highest in the nucleus
where RCC1 (dark orange), the guanine exchange factor (GEF) responsible for its activation, is located. RanGDP concentration is
highest in the cytoplasm. RanGAP (light orange), the GTPase activating protein (GAP) responsible for Ran’s inactivation, has been
shown to interact with NUPs of the cytoplasmic filaments, increasing the probability of it coming into contact with GTP-bound
importin-β1 exiting via the NPC.
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Interaction of importin-α with importin-β1
Importin-α and importin-β1 form a heterodimer before binding the cargo protein. It has been
shown that importin-α is able to bind cargo protein in the absence of importin-β1 but that binding
is greatly increased in the presence of importin-β1 (14). This is due to auto-inhibition of
importin-α. Importin-α is composed of two functional domains: a short N-terminal importin-β
binding (IBB) domain and a large NLS-binding domain. In the absence of importin-β1, the IBB
acts as a pseudo-NLS, binds the NLS-binding domain and thus results in steric interference,
greatly reducing cargo protein binding (92,93).

Interaction of importin-α with the cargo protein
Importin-α acts as a transport receptor for proteins directed to the nucleus. It does so by directly
binding NLSs within cargo proteins. A NLS can be described as being either monopartite, having
a single cluster of basic residues, or bipartite, containing two clusters of basic residues separated
by a mutation tolerant linker sequence (94). Early work on bipartite signals described the linker
sequence as being 9 to 12 amino acids long, though recent work has shown that the sequence can
be as long as 29 amino acids (95). Basic residues of NLSs bind at two sites along the concave
surface of importin-α. This surface is composed of ten armadillo repeats (ARM) with strictly
conserved tryptophan and asparagine residues (96). The major NLS binding site, which is where
monopartite sequences bind, is formed from ARMs 2-4. Bipartite sequences, however, bind both
the major binding site and a second pocket formed by ARMs 7-9, termed the minor binding site
(97). This direct binding facilitates nuclear import by linking the cargo protein to importin-β1.

Interaction between importin-β1 and its partners deposits cargo proteins
into the nucleus
Once formed, the cargo-importin complex moves into the nucleus through the interaction of
importin-β1 with the nuclear pore complex. Importin-β1 interacts with FG-rich NUPs located on
the cytoplasmic filaments of the NPC and is shuttled through the central pore into the nucleosol
(15). Within the nucleus, RanGTP binds importin-β1, inhibiting its interaction with importin-α.
When the IBB site of importin-α is no longer bound by importin-β1, the IBB acts as a high
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affinity pseudo-NLS, displacing the cargo protein and releasing it into the nucleus (98). The
cargo protein will remain in the nucleus unless actively exported by the nuclear export pathway.
This process also recycles importin-α and importin-β1 into the cytoplasm and is dependent on
RanGTP (16).

The Ran Cycle
The energy for nuclear import is provided by the Ran cycle. Ran, a member of the small Ras
GTPase family, cycles between a GTP- and a GDP-bound state. A Ran gradient is established in
the cell by the asymmetrical distribution of Ran regulators. The guanine exchange factor (GEF)
responsible for RanGTP, known as regulator of chromosome condensation (RCC1), contains an
NLS and is localized predominantly in the nucleus (99). Binding of RCC1 to Histone H2A and
H2B increases RCC1 GEF activity by two fold (100). The GTPase Activating Protein (GAP)
responsible for RanGDP, known as RanGAP, localizes predominantly to the cytoplasm and can
interact with RanBP1 and the nucleoporin NUP358 (also known as RanBP2) on the cytoplasmic
filament (15). This compartmentalization of regulators creates a high concentration of RanGTP
within the nucleus, which is quickly converted to RanGDP upon exiting via the nuclear pore.
This distribution is critical to nuclear import as the phosphorylation state of Ran affects
karyopherin-cargo interactions in classical nuclear import.

1.4.3

Alternative nuclear import mechanisms

As mentioned, classical nuclear import accounts for approximately 45% of import (11); the
remaining 55% of import is determined by alternate mechanisms. In addition to the well
described classical model of nuclear import, there exist less well understood mechanisms. In
application, these are easy to distinguish from the classical pathway as they do not utilize the
importin-α subunit: they use a different adaptor protein or possibly bind karyopherin-β subunit
directly.
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Alternative import pathways using importin-β1
Import of the uridine-rich small nuclear ribonucleoprotein particles (U snRNPs), which are
spliceosomal subunits, uses a similar process to classical nuclear import, though it uses an
alternate adaptor protein. Rather than importin-α, U snRNPs bind the adaptor protein snurportin1. Snurportin-1 contains an IBB similar to importin-α and is able to bind importin-β1 to facilitate
nuclear import (101). Rather than a NLS, snurportin-1 recognizes its cargo by an m3G-cap on the
spliceosomal RNA (102–104).

Additionally, importin-β1 is capable of binding some cargo proteins directly without the use of
an adaptor protein. These proteins include ribosomal proteins (105), parathyroid hormone-related
protein (PTHrP) (106), CREB (107), cyclin B1 (108), the HIV proteins Rev and Tat (109), the
human T-cell leukemia virus type 1 (HTLV-1) protein Rex (110), and others. Not all of these
proteins bind importin-β1 at the same site as importin-α. For example, the binding site for PTHrP
only partially overlaps the IBB binding site. The superhelix of importin-β1 is composed of 19
HEAT repeat domains. HEAT repeat domains get their name from four proteins in which they
have been found: Huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the
yeast kinase TOR1. Importin-α binds to repeats 2-11 and PTHrP binds to repeats 7-19 (111).

Alternative import pathways using other karyopherin-β family members
Karyopherin-β2, another member of the β-karyopherin subfamily, is responsible for the nuclear
import of over 20 proteins involved in mRNA processing, including FUS (68), EWS (73), and
hnRNP A1 (66). These proteins sometimes use the PY-NLS, named for a conserved PY Cterminal sequence. The ALS-linked protein EWS, for example, uses this type of NLS (72,73).
PY-NLS are characterized as being structurally disordered, having an overall basic character, and
as having the C-terminal consensus sequence R/H/KX2-5PY (112).
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In addition to importin-β1 and karyopherin-β2, at least 8 other β-karyopherins play a role in
nuclear import. However, much is still unknown about the cargo of these proteins and the
mechanism by which they interact (91).

1.5 Pleckstrin homology domains
Pleckstrin homology (PH) domains are widely believed to contribute to the subcellular
localization of proteins. They are invariably located at the C-terminus of a Dbl Homology (DH)
domain and together these two domains are often sufficient to perform guanine exchange (17).
The DH domain catalyzes exchange of GDP for GTP, activating the GTPase. The mechanism by
which the PH domain contributes to guanine exchange is not fully known, though it is believed
to be necessary to localize the protein to substrate rich membranes by binding phosphoinositides
(113).

PH domains lack consensus gene homology and instead are identified by their characteristic
molecular structure: a seven-stranded β-sandwich structure with a C-terminal α-helix (114). PH
domains get their name from the platelet protein Pleckstrin, which contains two PH domains.
Figure 3 shows the N-terminal PH domain of Pleckstrin (115). It is believed that PH domains
facilitate membrane binding through interactions between basic residues located along the βsandwich structure and phosphoinositides (PtdIns) embedded within the membrane. Only a
minority of PH domains show high affinity for PtdIns though and the true mechanism of
localization has yet to be elucidated (113).

To date, no PH domain has been shown to contribute to nuclear import. An NLS was, however,
found within the intervening sequence of a Split-Pleckstrin Homology (sPH) domain (18). Like
PH domains, sPH domains share the characteristic 7 β-sandwich structure with a C-terminal αhelix. However, they contain an autonomously folded, intervening module. In the absence of this
intervening module, the sPH domain is still capable of folding to its characteristic molecular
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Figure 3: The N-terminal PH domain of Pleckstrin. The consensus characteristics of PH domains: 7 β-sandwich structure (yellow)
with a C-terminal α-helix (pink). This figure was created using the protein sequence from PubMed. The model was created using ITasser (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (116–118) and manipulated using RasMol v2.7.5 (Bernstein + Sons, Shirley
New York).
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structure (119,120). The intervening sequence within the sPH domain of phosphoinositol 3kinase enhancer (PIKE) has been shown to contain an NLS necessary for its localization to the
nucleus. The mechanism by which this NLS affects nuclear import – classical vs non-classical
pathway – has not been identified. The NLS, however, has been shown to increase the affinity of
the PH domain for membrane binding (18). This may be because basic residues mediate both the
binding of PH domains to PtdIns within membranes and interactions between NLSs and
importin-α in classical nuclear import. Therefore, PH domains represent a likely location of NLS
activity.

1.6

Rho guanine nucleotide exchange factor

Rho guanine nucleotide exchnage factor (RGNEF) is a 180 kDa protein unique in the human
proteome for its ability to act both as a guanine exchange factor (GEF) and in its ability to bind
RNA (19). Figure 4 shows the domains of RGNEF. Our lab identified RGNEF as a potential
ALS-linked protein after confirming its ability to directly bind to and destabilize NEFL mRNA
(19,22).

In addition to its role alongside TDP-43 as a regulator of NEFL mRNA stability, RGNEF shows
further evidence of involvement in ALS. ALS-specific mutations have been identified by three
independent labs (20,121,122). Figure 5 shows these mutations in ARHGEF28, the gene which
encodes RGNEF. The deletion of a single nucleotide leading to either a frameshift or a splicing
mutation has been observed for ALS cases. The resulting protein is predicted to be either 319 or
259 amino acids long and to lack functional domains including the RNA binding, DH and PH
domains (20).

Ubiquitinated aggregates containing RGNEF have also been found in ALS spinal motor neurons.
Our lab has shown that RGNEF NCIs can be observed in all variants of ALS except those with a
mutation in the gene superoxide dismutase 1 (SOD1). This includes cases of fALS with
identified C9orf72 expanded repeats, TDP-43 mutations, FUS mutations, and fALS cases for
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Figure 4: The domains of RGNEF. The leucine rich domain (orange) extends from amino acids 97 – 206. The Ankyrin Repeat
domain (black line) partially overlap this region and extends from amino acids 153-216. The Cysteine-rich Zinc binding domain
(yellow) extends from amino acids 651-697. The Dbl Homology (DH) domain (blue) extends from amino acids 850-697. The
Pleckstrin Homology (PH) domain (green) extends from amino acids 1082-1201. The RNA binding domain (red) extends from amino
acids 1257-1614. The RNA binding domain overlaps the FAK binding domain (black line) which extends from amino acids 1292 –
1301. The RNA binding domain partially overlaps the putative microtubule binding domain which extends from amino acids 1731
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Figure 5: The frameshift mutation identified in ARHGEF28. The mutation observed in ARHGEF28, the gene which encodes for
RGNEF, is predicted to cause a frameshift mutation resulting in a premature truncated protein. The resulting protein is predicted to be
either 319 or 259 amino acid. Either protein would result in the complete loss of many of the functional domains of RGNEF, including
the DH, PH, and RNA binding domains. The resulting proteins would express only the Leucine-Rich region and the Ankryn Repeats.
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which the underlying genetic mutation is unknown. RGNEF immunoreactive inclusions are also
seen in sALS, some of which harbour pathogenic C9orf72 expansions in the absence of any
family history of ALS. RGNEF also strongly co-localizes with TDP-43 and FUS
immunoreactive NCIs in sALS motor neurons (21), further strengthening the relationship
between RGNEF and those proteins that undergo nuclear depletion in ALS. Despite the overlap
between RGNEF and other ALS-linked proteins, the mechanism by which RGNEF contributes
to ALS pathology has not been elucidated. One potential way RGNEF may play a role in disease
pathology is by providing cytoprotection to stress. Our lab has previously shown that HEK293T
cells transfected with RGNEF showed increased survival under oxidative and osmotic stress
conditions (123). Interestingly the data did not support the hypothesis that RhoA activation via
the GEF activity may be responsible for this protection.

Despite previous literature having identified RGNEF within the nucleus (19), to date no
mechanism for RGNEF nuclear import has been identified. As described in section 1.4, the
maximum size for diffusion into the nucleus described in the literature is 110 kDa (89); RGNEF,
with a molecular weight of 180 kDa, should not be able to penetrate the nuclear envelope
without active transport. Therefore, it is likely that RGNEF contains a NLS. Of the domains in
RGNEF, only the pleckstrin homology domain is linked to subcellular localization. Therefore,
the PH domain of RGNEF is a likely site for the location of a NLS responsible for its nuclear
import.

1.7 Hypothesis
Given the canonical function of PH domains in GEF activity, I hypothesize that the PH domain
of RGNEF will play a role in its subcellular localization. Specifically, I hypothesize that it may
contain a NLS responsible for RGNEF nuclear import.
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Chapter 2
2

Specific Aims & Overview

2.1 Specific Aims
2.1.1 Aim 1: Determine the effects of the PH domain on subcellular
localization of RGNEF
My first aim was to determine whether the PH domain of RGNEF contributes to its subcellular
localization. To accomplish this I performed a series of polymerase chain reactions (PCRs) using
flanking primers, which resulted in the creation of an RGNEF construct lacking the PH domain
(RGNEF-ΔPH). The effects of this deletion were analyzed by immunocytochemistry (ICC) with
confocal microscopy as well as by cellular fractionation followed by Western blot. All
experiments were performed in HEK293T cells.

2.1.2 Aim 2: Determine the mechanism for the apparent PH domain
dependent nuclear import of RGNEF using in silico techniques
My second aim was to use in silico techniques to determine the mechanism by which the PH
domain of RGNEF contributes to its nuclear import. An online service, cNLS mapper (http://nlsmapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) (97,124,125), was used to identify a
putative NLS responsible for nuclear import via the classical import pathway. The online
modeling software I-Tasser (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (116–118) was
then used to determine the molecular structure of the PH domain and RasMol (Bernstein + Sons,
Shirley New York) was used to manipulate the image.
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2.1.3 Aim 3: Confirm the functionality of the putative NLS in the PH domain
of RGNEF
My third aim was to confirm the existence of the putative NLS within the PH domain of
RGNEF. The basic residues of the putative NLS were point-mutated to neutral alanines creating
a full length construct lacking the NLS (RGNEF-mNLS). We next created two sets of constructs
expressing only the regions of interest. The first used the peGFP-C1 vector. Three constructs
were created using this vector expressing the endogenous PH domain (PH-40 kDa), the
endogenous NLS (NLS-26 kDa) or the PH domain with point-mutations (mNLS-40 kDa) with
N-terminal GFP-tag. A second set of constructs used the pHM830 vector which causes the
protein to express with both N-terminal GFP-tag and the addition of LacZ to the C-terminal. The
endogenous PH domain (PH-160 kDa) and the PH domain with point-mutations (mNLS-160
kDa) were created.

The subcellular localization of all of these constructs was measured using confocal microscopy.
Results obtained using the full length constructs – RGNEF, RGNEF-ΔPH, and RGNEF-mNLS –
were confirmed by subcellular fractionation in HEK293T cells and by transfection of SH-SY5Y
cells with ICC and confocal microscopy.

2.2 Cell lines and transfections
Two cells lines were used in these experiments: HEK293T and SH-SY5Y cells. The HEK293T
cell line was chosen because it expresses the low molecular weight neurofilament mRNA (NEFL
mRNA) (126) and because it is more amenable to transfection than neuronal cell lines. The SHSY5Y cell line was chosen because it is a neuroblastoma cell line that can be differentiated to
yield a dopaminergic neuron-like phenotype which expresses neuron specific proteins including
neurofilaments (127).

Both cell lines were maintained in Dulbecco’s modified eagle’s medium (DMEM, Gibco, Life
Technologies Inc., Burlington, Ontario) supplemented with 10% fetal bovine serum (Gibco, Life
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Technologies Inc., Burlington, Ontario) and kept in a water-jacketed 37OC 5% CO2 incubator
(Forma Scientific, Thermo Fisher Scientific, Ottawa, Ontario).

Prior to transfection, SH-SY5Y cells were differentiated using retinoic acid to yield a neuron-like
phenotype. To do this, non-differentiated cells at approximately 40% confluency were treated
with 10 μM retinoic acid (Sigma-Aldrich, Oakville, Ontario) in DMEM media and incubated for
3 days. Because retinoic acid is light sensitive, plates were kept in the dark during this period.

2.3 RGNEF Constructs
In order to elucidate the role of the PH domain, 7 constructs were created. The primers for these
processes are listed in Table 2. All mutagenesis PCRs were done using Pfu DNA polymerase
(Thermo Fisher Scientific, Ottawa, Ontario). Figure 6 shows the 7 constructs created in this
project. The full length RGNEF was created previously in our lab. RGNEF-ΔPH was created to
study subcellular localization of RGNEF lacking the PH domain; it is a deletion of base pairs
3249-3603 (amino acids 1083-1201) with Kpn1 and Xho1 restriction sites on the 5’- and 3’terminal, respectively. We then created a full length RGNEF that contained point-mutations at
four sites designed to mutate the basic residues (arginine and lysine) of the putative NLS to
alanines; this was called RGNEF-mNLS.
Having compared subcellular localization of these full length constructs - RGNEF, RGNEFΔPH, and RGNEF-mNLS - we next isolated the effects of only the regions of interest. For this
purpose two sets of constructs expressing only specific regions were created. The first set used
the peGFP-C1 vector which resulted in N-terminal GFP-tagged proteins. PH-40 kDa and NLS26 kDA expressed only the PH domain (amino acids 1083-1202) or NLS (amino acids 11001128) of endogenous RGNEF, respectively. Their names originate from their predicted
molecular mass: 40 kDa and 26 kDa. These used our full length RGNEF as a template. A third
construct, mNLS-40 kDa, was created using RGNEF-mNLS as a template and expressed the PH
domain of RGNEF-mNLS with point-mutations (amino acids 1083-1202; R1101A, K1103A,
K1120A, K1123A).
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Table 2: The primers used in PCR to generate the different RGNEF constructs.
Name
RGNEF ΔPH

RGNEF mNLS

PH-40 kDa /
mNLS-40 kDa
NLS-26 kDa
PH-160 kDa /
mNLS-160 kDa

Forward or reverse
primer
Forward (1)
Reverse (1)
Forward (2)
Reverse (2)
Forward (1) - R1101A
Reverse (1) - R1101A
Forward (2) - K1103A
Reverse (2) - K1103A
Forward (3) - K1120A
Reverse (3) - K1120A
Forward (4) - K1123A
Reverse (4) - K1123A
Forward
Reverse
Forward
Reverse
Forward

DNA sequence (5' to 3')
ATTGGTACCATGGAGTTGAGCTGCAGCGAA
GAAGACAAGAGGAAAGCTGAAGCCAGAGTG
CCTCTTGTCTTCTTCACTCATCAGTGCCTGCTT
AGACTCGAGCACCTTGAGGTCTACTTGATGTT
GTTTACTGGAAAACTGCTACAGGTGCTTTCAAAGATATCCTAGCTCTACT
AGTAGAGCTAGGATATCTTTGAAAGCACCTGTAGCAGTTTTCCAGTAAAC
GAAAACTGCTACAGGTGCTTTCGCAGATATCCTAGCTCTACTTCTA
TAGAAGTAGAGCTAGGATATCTGCGAAAGCACCTGTAGCAGTTTTC
GATGTGCTGCTCTTTTTACAAGAAGCAGACCAGAAATACATCTTTGCAGC
GCTGCAAAGATGTATTTCTGGTCTGCTTCTTGTAAAAAGAGCAGCACATC
CTCTTTTTACAAGAAGCAGACCAGGCATACATCTTTGCAGCCGTTGATCA
TGATCAACGGCTGCAAAGATGTATGCCTGGTCTGCTTCTTGTAAAAAGAG
TACTCGAGATGAAAGGACTCTGTTATATGATGGC
ACTGGTACCTCAATCAGATTCACTTGTCCTTCC
TGCTCGAGATGGTCGTTTCAAAGATATCCTAG
CACTGGTACCTCATGCAAAGATGTATTTCTGGTCTTTTTCTTG
AGGCTAGCGAAAGGACTCTGTTATATGATG

Reverse
TATCTAGAATCAGATTCACTTGTCCTTCCC
*Restriction enzyme sequences are underlined. XhoI = CTCGAG; KpnI = GGTACC; NheI = GCTAGC; XbaI= TCTAGA
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Figure 6: Comparison of the different constructs of RGNEF. Full length RGNEF was
previously created in our lab. RGNEF-ΔPH and RGNEF-mNLS were ligated into the
pcDNA3.1A(+)myc/his A plasmid resulting in the expressed protein containing a myc tag on
their C-terminal. PH-40 kDa, NLS-26 kDa, and mNLS-40 kDa were all ligated into the eGFP-C1
vector resulting in the expressed protein containing GFP on their N-terminal. PH-160 kDa and
mPH-160 kDa were ligated into the pHM830 vector resulting in the expressed protein containing
GFP on their N-terminal and LacZ protein on their C-terminal.
RGNEF-ΔPH (deletion of amino acids 1082-1201; this construct lacks the PH domain)
RGNEF-mNLS (mutation of residue 1101 from an arginine to an alanine and of residues 1103,
1120 and 1123 from lysines to alanines; mutations in this construct are predicted to
eliminate the putative NLS, thereby reducing import into the nucleus)
PH-40 kDa (expression of only the PH domain – residues 1082-1201 – with N-terminal GFP;
this construct is predicted to localize to the nucleus)
NLS-26 kDa (expression of only the putative NLS – residues 1100-1128 – with N-terminal GFP;
this construct is predicted to localize to the nucleus)
mPH-40 kDa (expression of only the mutated PH domain; residues 1082-1201 of the RGNEFmNLS construct; contains the four mutations R1101A, K1103A, K1120A, and K1123A;
contains N-terminal GFP and C-terminal LacZ; predicted to show reduced levels of nuclear
localization compared with PH-40 kDa)
PH-160 kDa (expression of only the PH domain – residues 1082-1201 – with N-terminal GFP
and C-terminal LacZ; this construct is predicted to localize to the nucleus)
mPH-160 kDa (expression of only the mutated PH domain; residues 1082-1201 of the RGNEFmNLS construct; contains the four mutations R1101A, K1103A, K1120A, and K1123A;
contains N-terminal GFP and C-terminal LacZ; predicted to show reduced levels of nuclear
localization compared with PH-40 kDa)
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The second set of constructs designed to isolate the effects of certain regions utilized the
pHM830 vector (Addgene, Cambridge, Massachusetts) which encodes for an N-terminal GFPtag and C-terminal addition of the LacZ protein. I designed these constructs but due to time
constraints their synthesis was carried out by Dr. Cristian Droppelmann, a post-doctoral research
associate in our lab. Similar to before, constructs expressing the PH domains of endogenous
RGNEF and RGNEF-mNLS were created: PH-160 kDa and mNLS-160 kDa. With the addition
of both the N-terminal GFP-tag and the C-terminal addition of LacZ protein the total molecular
weight of the proteins was predicted to be 160 kDa.

2.3.1 PH domain deletion (RGNEF-ΔPH)
In order to determine the role of the PH domain on RGNEF localization, a construct lacking the
domain was created. Given the size of the domain (357bp) and its location towards the centre of
the gene, it was necessary to perform site-directed mutagenesis by primer extension. This
process was first described by Ho et al. (128). In this process (see Figure 7) two independent
PCR reactions using flanking internal primers produce fragments encoding the 5’ and 3’ outside
of the PH domain (see top two panels of Figure 7). The flanking internal primers yield constructs
with complementary overlap regions. A third PCR reaction is performed in which the two PCR
products are mixed and their complementary regions hybridize, allowing one construct to act as
the template for the other. The product of this PCR reaction is the desired construct: RGNEF
lacking the PH domain. In the final PCR reaction, the two external primers are added to the
product in order to amplify the yield. In my protocol, the reaction of PCR 3 underwent 10 cycles
of extension, the external primers were added directly to the sample, and 40 more cycles
occurred. Table 3 shows the program conditions for all PCR protocols and Table 2 shows the list
of primer used. Note that following PCR reactions 1, 2 and 4 it was necessary to purify the
product by gel extraction using a NucleoSpin Gel Extraction Kit (Macherey-Nagel Inc.,
Bethlehem Pennsylvania, USA) and DNA concentration were quantified using a Nanodrop
Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts USA).
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Figure 7: Flanking PCR. The mechanism for performing a flanking PCR. Green arrows represent primers. Yellow tails represent the
added restriction sites (Kpn1 and Xho1). Purple tails represent the complementary shared sequence. The initial two PCR reactions use
primers which result in complementary sequences. In the third PCR reaction, the final desired construct is created (in this case
RGNEF-ΔPH) by adding the N- and C-terminal fragments in the first two PCRs together. Pfu DNA polymerase binds the
complementary region and used the opposite fragment as a template for synthesis. In PCR 4, external primers are added, allowing for
amplification of the desired product.
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All reactions were carried out using Pfu DNA polymerase (Thermo Fisher Scientific, Waltham,
Massachusetts USA). The manufacturer’s protocol was followed, though dimethyl sulfoxide
(DMSO; VWR International, Mississauga, Ontario) was added to a final concentration of 5%;
this was done to reduce the non-specific amplification. The external primers encoded for the
addition of the Kpn1 and Xho1 restriction sites to the 5’ and 3’ ends, respectively.

Following the final PCR reaction the product was purified by gel extraction and the insert was
prepared for ligation into the pGEM-T Easy backbone using the pGEM –T Easy Vector System
(Promega Corporation, Madison, Wisconsin, USA). The pGEM-T Easy is convenient for easy
ligation and amplification of the insert. As described in the protocol provided by the
manufacturer, the pGEM-T vector comes with 3’T-overhangs at the insertion site for simple AT
Cloning. For this reason our PCR product was first a-tailed using Taq DNA polymerase. Ligation
occurred as described in the protocol with the maximum volume of PCR product (3 µl) added to
the reaction.

The product of the ligation was used to transform chemically competent DH5α Escherichia coli
(E. coli, Invitrogen, Life Technologies Inc., Burlington, Ontario). Bacteria were plated onto an
agar plate containing the selective antibiotic ampicillin and incubated at 37OC overnight.
Colonies were selected and grown in LB Broth with 0.1 μg/μl ampicillin at 37oC for 15 hours.
DNA was extracted by Miniprep kit (Invitrogen, Life Technologies Inc., Burlington, Ontario) for
subsequent cloning. Colonies were screened to contain the insert and plasmid first by 1% agar
gel and then by sequencing at the London Regional Genomics Centre (London, Ontario).

Given the utility of its affinity tag system, appropriate DNA was then ligated into the pcDNA
3.1(+)/myc-His A backbone, which when expressed adds a myc-tag to the C-terminal end of the
protein. The insert was liberated from the pGEM vector using the Kpn1 and Xho1 restrictions
sites added to the construct by our external primers. The pcDNA 3.1(+)/myc-His A was likewise
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Table 3: The conditions for Flanking Primer PCR
Stage 1

PCR 2: C-Terminal Fragment

&

3:00 min

Stage 2

42 Cycles

95oC

0:45 min

62oC

0:45 min

72oC

6:30 min

Stage 3
72oC

1 Cycle
20:00 min

Stage 4

1 Cycle
∞

4oC
PCR 3: Final Construct

Stage 1
95oC

1 Cycle
3:00 min

Stage 2

10 Cycles

95oC

0:45 min

58oC

0:45 min

72oC

9:45 min
Add external primers

Stage 3

PCR 4: Amplification

PCR 1: N-Terminal Fragment

95oC

1 Cycle

40 Cycles

95oC

0:45 min

60oC

0:45 min

72oC

9:45 min

Stage 4
72oC
Stage 5
4oC

1 Cycle
20:00 min
1 Cycle
∞
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cut within the multiple cloning site. Both Kpn1 and Xho1 were purchased from Invitrogen
(Invitrogen, Life Technologies Inc., Burlington, Ontario). The pcDNA 3.1(+)/myc-His A was
then dephosphorylated using shrimp alkaline phosphatase. The insert and backbone were
incubated with T4 DNA Ligase (Promega Corporation, Madison, Wisconsin, USA) overnight at
room temperature.

As previously described, the ligation product was used to transform chemically competent DH5α
E. coli (Invitrogen, Life Technologies Inc., Burlington, Ontario). Bacteria were plated on
ampicillin containing agar plates and grown overnight. Colonies were selected, grown in LB
broth with 0.1 μg/μl ampicillin overnight, and a Miniprep kit (Invitrogen, Life Technologies Inc.,
Burlington, Ontario) was used to extract DNA. The DNA was screened both by 1% agar gel and
then by DNA sequencing. The construct was then used to transfect of mammalian cell lines (See
2.3 Transfection).

2.2.2 NLS point-mutations (RGNEF-mNLS)
Having identified four residues likely to act as the putative NLS, we performed site-directed
mutagenesis to point-mutate these basic residues to neutral alanine residues. The primers for this
are listed in Table 2. Four sets of primers and four successive PCR reactions were necessary to
accomplish this task. The reactions were performed in sequence: the product of the first PCR
became the template for the second reaction and so on. The first reaction mutated arginine
residue at 1101 to an alanine. The remaining mutations changed lysine residues to alanine
residues and occurred at sites 1103, 1120, and 1123.

All four reactions utilized the QuickChange Lightning Multi Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, California). All four PCR were performed as described in
the protocol provided in the QuickChange Kit. Following each PCR reaction, XL10-Gold
Ultracompetent E. coli (Agilent Technologies, Santa Clara, California) were transformed using
the PCR product as per the protocol provided in the QuickChange Kit. E. coli cells were plated
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on agar plates containing the selective antibiotic ampicillin. Plates were incubated at 37OC
overnight. Colonies were selected from these plates, grown in LB broth containing 0.1 μg/μl
ampicillin overnight, purified by Miniprep kit (Invitrogen, Life Technologies Inc., Burlington,
Ontario) and the DNA was screened by 1% agarose gel and DNA sequencing at the London
Regional Genomics Centre (London, Ontario). Note that because site-directed mutagenesis
occurs while the coding sequence of the gene is still within the circular plasmid - pcDNA
3.1(+)/myc-His A in this case – it was not necessary to ligate the PCR product into the plasmid
prior to transformation as it was in the PH deletion protocol.

2.3.3 PH-, NLS- and mNLS-only constructs in peGFP-C1 (PH-40 kDa,
NLS-26 kDa, & mNLS-40 kDa)
In order to isolate the localization effects of the PH domain without the influence of the
remainder of the protein, three constructs were created: one composed of only the PH domain
(amino acids 1082 – 1201), one composed of only the NLS sequence (amino acids 1100 -1128),
and one composed of only the PH domain of the RGNEF-mNLS construct created in section
2.2.2 (amino acids 1082 – 1201; R1101A, K1103A, K1120A, K1123A). The primers for these
are listed in Table 2. Notice in Figure 6 that, similar to those for the ΔPH construct, the primers
for these constructs include the addition of an Xho1 and Kpn1 restriction site, though at opposite
ends.

Following the PCRs, the products were purified by gel extraction using NucleoSpin Gel
Extraction Kit (Macherey-Nagel Inc., Bethlehem Pennsylvania, USA) and concentration was
determined using a Nanodrop Spectrophotometer (Thermo Fisher Scientific, Waltham,
Massachusetts USA). Xho1 and Kpn1 (Invitrogen, Life Technologies Inc., Burlington, Ontario)
restriction enzymes were used to digest the product of these PCR reactions. The peGFP-C1
backbone was also cut with Kpn1 and Xho1 restriction enzymes and dephosphorylated using
shrimp alkaline phosphatase. Each construct was independently ligated into the peGFP-C1 vector
using T4 Ligase (Promega Corporation, Madison, Wisconsin, USA). Following ligation, DH5α
E. coli (Invitrogen, Life Technologies Inc., Burlington, Ontario) were transformed with the
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respective products. Transformed cells were plated on agar plates with the selective antibiotic
kanamycin. Plates were incubated at 37OC overnight. Colonies were selected and were grown
overnight in LB broth containing 0.1 μg/μl kanamycin on an orbital shaker at 300 rpm at 37OC.
A Miniprep kit (Invitrogen, Life Technologies Inc., Burlington, Ontario) was used to extract
DNA from E. Coli. The DNA was then confirmed first by 1% agarose gel and by DNA
sequencing London Regional Genomics Centre (London, Ontario).

2.3.4 PH- and mNLS-only constructs in pHM830 (PH-160 kDa & mNLS160 kDa)
Because nuclear localization is dependent on molecular weight, we next created constructs with
molecular weight of 160 kDa using the pHM830 vector (Addgene, Cambridge, Massachusetts).
Due to time constraints, I designed these constructs though Dr. Cristian Droppelmann, a postdoctoral research associate in our lab, carried out the experiments. The primers for these
constructs are listed in Table 2. These primers encode for the addition of NheI and XbaI sites to
the 5’ and 3’ ends respectively.

Similar to in 2.3.3 after PCR, the products were purified by gel extraction using NucleoSpin Gel
Extraction Kit (Macherey-Nagel Inc., Bethlehem Pennsylvania, USA) and concentration was
determined using a Nanodrop Spectrophotometer (Thermo Fisher Scientific, Waltham,
Massachusetts USA). NheI and XbaI (Invitrogen, Life Technologies Inc., Burlington, Ontario)
restriction enzymes were used to digest the product of these PCR reactions. The pHM830
backbone was also cut with NheI and XbaI restriction enzymes and dephosphorylated using
shrimp alkaline phosphatase. Each construct was independently ligated into the pMH830 vector
using T4 Ligase (Promega Corporation, Madison, Wisconsin, USA). Following ligation, DH5α
E. coli (Invitrogen, Life Technologies Inc., Burlington, Ontario) were transformed with the
respective products. Transformed cells were plated on agar plates with the selective antibiotic
ampicillin. Plates were incubated at 37OC overnight. Colonies were selected and were grown
overnight in LB broth containing 0.1 μg/μl ampicillin on an orbital shaker at 300 rpm at 37OC. A
Miniprep kit (Invitrogen, Life Technologies Inc., Burlington, Ontario) was used to extract DNA
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from E. Coli. The DNA was then confirmed first by 1% agarose gel and by DNA sequencing
London Regional Genomics Centre (London, Ontario).

2.4 Seeding and transfection of mammalian cell lines
Both HEK293T cells and SY5Y cells were used for these experiments. All cells used in this
experiment were maintained in a water-jacketed 37OC 5% CO2 incubator (Forma Scientific,
Thermo Fisher Scientific, Ottawa, Ontario).

For immunocytochemistry (ICC), a coverslip was placed at the bottom of a 6-well plate. The
coverslip was coated with 1X attachment factor (Gibco, Life Technologies Inc., Burlington,
Ontario) to increase cell adhesion. HEK293T cells were seeded at 230 000 cells per well. Cells
were allowed to incubate one day until they reached approximately 70% confluency. They were
then transfected using Lipofectamine 2000 (Thermo Fisher Scientific, Ottawa, Ontario) using 2
µg of DNA and 5 µl of Lipofectamine 2000 per well. As per the protocol provided, cells were
incubated with Lipofectamine and DNA for 3 hours. Cells were incubated overnight in DMEM
media described above.

The HEK293T cell line was also used for the purpose of fractionation. The bottom of a 150mm
plate was coated with 1X attachment factor (Gibco, Life Technologies Inc., Burlington, Ontario).
Cells were seeded at 2 200 000 per 150 mm plate and 26 µg of DNA and 65 µl of Lipofectamine
2000 were used per plate. All other conditions were the same.

The SH-SY5Y cell line was used for ICC and confocal microscopy. Again, coverslips were
coated with 1X attachment factor (Gibco, Life Technologies Inc., Burlington, Ontario) and
placed in the bottom of a 6-well plate. As described in section 2.2, SH-SY5Y cells were seeded
at approximately 40% confluency and treated with 10 µM retinoic acid for 3 days prior to
transfection. On the day of transfection, SH-SY5Y cells were at approximately 80% confluency.
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2.5 µg of DNA and 7.5 µl of Lipofectamine 2000 were added per well. Cells were incubated
with Lipofectamine and DNA for 3 hours. Afterwards cells were incubated for 48 hours in
DMEM media with 10 µM retinoic acid.

2.5 Immunocytochemistry (ICC) and confocal microscopy
Following transfection, immunocytochemistry (ICC) was performed to visualize protein
localization. Coverslips were fixed in 4% paraformaldehyde in 1X PBS. Coverslips were then
washed with 1X PBS three times and permeabilized using 0.2% Triton X-100 in 1X PBS for 10
minutes. Coverslips were washed once and then incubated in 50 mM Ammonium Chloride in 1X
PBS for 30 minutes in order to quench aldehyde groups and reduce background staining. Nonspecific antibody interactions were reduced by incubating cover slips for 60 minutes at room
temperature in blocking solution: 8% bovine serum albumin (BSA; Fisher Scientific Company,
Ottawa, Ontario) in 1X PBS. Primary antibodies were diluted in blocking solution as described
in Table 4. Coverslips were incubated in primary antibody for 90 minutes at room temperature in
a humidifying chamber. Following incubation, coverslips were washed twice in blocking
solution. Fluorescent AlexaFluor® antibodies (Life Technologies), shown in Table 4, were
diluted in blocking solution and coverslips were incubated for 60 minutes at room temperature in
a humidifying chamber. In order to visualize nuclei, coverslips with HEK293T cells were then
incubated in 1 µg/mL Hoechst stain in PBS for 10 minutes. Coverslips with SH-SY5Y cells were
found to stain better with DAPI stain and so were incubated in 1 μg/mL DAPI stain in PBS for 7
minutes. Coverslips were washed, first with PBS and then with deionized water, and left to dry
overnight. Once dry, cover slips were mounted to frosted glass microscope slides using a
fluorescent mounting media (Dako Canada Inc., Burlington, Ontario).

All cover slips in Aim 1 were examined using a multi-photon confocal microscope (LSM 510
META; Carl Zeiss Canada Ltd., Toronto, ON) and ZEN software (Carl Zeiss Canada Ltd.,
Toronto, ON). All coverslips in Aim 3 were examined using a Confocal Laser Scanning Platform
Microscope (SP8; Leica Microsystems Inc, Richmond Hill, ON) and LAS X software (Leica
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Table 4: The antibodies used in immunocytochemistry for confocal microscopy
Name

c-Myc
(monoclonal)

Species

Dilution

Manufacturer
Cedarlane

Mouse

1:250

(Burlington,
Ontario)

Sigma-Aldrich
β III Tubulin

Rabbit

1:60

(Oakville,
Ontario).

Secondary Antibody
Goat α- Mouse, 488 nm
absorbance, Life
Technologies (titre:
1:800)
Goat α-Rabbit, 546 nm
absorbance, Life
Technologies (titre:
1:800)

41
Microsystems Inc, Richmond Hill, ON). The optical settings used for confocal microscopy in
aim 3 are listed in Appendix A. Both ZEN and Las X software were used to generate intensity
profiles which aided in cell counting for nuclear localization.

2.6 Fractionation protocol
Figure 8 shows the fractionation protocol used to isolate nuclear from cytoplasmic cellular
fractions (129). Cells were seeded on a 150 mm plate at 2 200 000, allowed to incubate
overnight, and were transfected as described in section 2.4. Twenty-four hours after transfection
plates were fractionated. Cells were washed once with 1X PBS and then semi-permeabilized
using 42 µg/ml digitonin (Sigma-Aldrich, Oakville, Ontario) dissolved in 1X NEH buffer. Cells
were incubated for 10 minutes at 4oC on bench top rocker (VWR International, Mississauga,
Ontario). The digitonin solution was collected and stored as the “cytoplasmic fraction”. Cells
were again washed with 1X PBS.

To each plate 500 μl of a low salt buffer was added, the surface of the plate was scraped using a
cell scraper, and the contents of the plate were collected and transferred to a Dounce
homogenizer (Corning Inc., Corning, New York, USA) where they were incubated on ice for 5
minutes. The low salt buffer contained 20 mM Hepes and 0.2 mM EDTA dissolved in 1X NEH
buffer. In order to prevent protein degradation, two protease inhibitor cocktails were added. The
first was the commercially available “cOmplete protease inhibitor” (Hoffman-La Roche Ltd.,
Mississauga, Ontario) dissolved in 1X NEH and diluted to 1X concentration. The second
contained 50 mM PMSF and 0.1 mg/ml TLCK dissolved in isopropanol.

Following incubation on ice, cells were homogenized by passing 50 strokes through tight-fitted
Dounce homogenizer. To the homogenate 500 μl of a high salt buffer was added and then passed
an additional 50 strokes. The high salt buffer contained 1 mM DTT, 300 mM NaCl, 200 mM
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Figure 8: Fractionation protocol. Transfected HEK293T cells are first washed with 1X PBS. Membranes of HEK293T cells are then
semi-permeabilized using a solution containing 42μg/ml digitonin (Sigma-Aldrich, Oakville, Ontario) dissolved in 1X NEH buffer.
Cells are incubated for 10 minutes at 4oC in this solution. The digitonin solution is then collected and saved as the Cytoplasmic
Fraction. Cells are washed once with 1X PBS. A Low Salt Homogenization Buffer is then added to the plate, the plate is scraped, the
contents are gathered, and the sample is incubated on ice in a Dounce homogenizer (Corning Inc., Corning, New York, USA). The
sample is then passed with 50 strokes using the tight fitting pestle. An equal volume of High Salt Homogenization Buffer is added and
an additional 50 strokes are performed. Finally, the sample is transferred to a centrifuge tube and centrifuged at 1000g for 10 minutes.
The pellet is saved as the Membrane Bound Proteins. The supernatant is saved as the Nucleosolic Proteins.
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Hepes, and 0.2 mM EDTA dissolved in 1X NEH as well as the two protease inhibitor cocktails
described above.

Following homogenization, the sample was collected and centrifuged at 1,000 g for 10 minutes
at 4OC. The resulting supernatant was collected and saved as the “nucleosolic fraction”.
Prior to analysis by Western blot, cytosolic fractions were concentrated using Microsep
microconcentrators (Pall Corporation, Port Washington, New York, USA) by centrifugation at
3000 g for 5 hours at 4OC. The protein concentration of all samples was determined using BioRad Dc protein assay according to the manufacturer’s protocol and colorimetric analysis was
performed using a microplate reader (Microplate Reader Benchmark; Bio-Rad Laboratories
Canada Ltd., Mississauga, Ontario) reading at 655 nm.

2.7 Western blot
Western blots were performed to study the expression of target proteins in samples.
Polyacrylamide gels were made at 10% and all samples were loaded at 50 μg per well based on
protein concentrations determined by Dc assay. A loading buffer containing 62.5 mM Tris base
(pH to 6.8), 2% SDS, 10% glycerol, 0.006% Bromophenol blue and 50% β-mercaptoethanol
diluted in water was prepared. Gels were run at a constant 100V for 2.5 hours. The running
buffer contained 50 mM Tris base, 200 mM glycine, and 2 mM SDS diluted in deionized water.
Gels were transferred to nitrocellulose membrane at a constant 300 mA for 90 minutes. Transfer
buffer was composed of 20% methanol dissolved in the above described running buffer. All
equipment used for running and transferring gels was manufactured by Bio-Rad (Bio-Rad
Laboratories Canada Ltd., Mississauga, Ontario). Nitrocellulose was kept at 4OC overnight in
washing solution. Washing solution was composed of 50 mM Tris base, 100 mM NaCl and 1%
Tween20 with pH 7.4.
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In order to reduce non-specific binding, nitrocellulose membranes were incubated in 5% skim
milk blocking solution in washing buffer at room temperature for 1 hour. Primary antibodies
were diluted in blocking solution and nitrocellulose membranes were incubated at room
temperature for 90 minutes on an orbital shaker. The nitrocellulose membrane was then washed
3 times using 5% milk blocking solution. Secondary antibody was diluted in 5% milk blocking
solution. The membrane was incubated in secondary antibody at room temperature for 60
minutes. Table 5 lists the primary and secondary antibodies used for Western blots.

After secondary antibody incubation, the nitrocellulose membrane was washed 3 times with
washing buffer. Each wash occurred at room temperature on orbital shaker for 10 minutes.
Western Lighting ECL reagents (PerkingElmer Woodbridge, Ontario) were used to generate
chemiluminescence signal. Nitrocellulose blots were incubated at room temperature in ECL
reagents for 2 minutes. Chemiluminescence was visualized using a Gel Doc system using Image
Lab 5.2 software (Bio-Rad Laboratories Canada Ltd., Mississauga, Ontario). Relative band
intensity was determined by densitometry using ImageJ (version 1.48v; National Institutes of
Health, USA).

2.8 In silico analysis
2.8.1 Molecular modeling
All molecular modeling was done using I-Tasser online (http://zhanglab.ccmb.med.umich.edu/ITASSER/). I-Tasser predicts protein structure using modeling by iterative threading assembly
simulation (116–118). The 3D model provided by I-Tasser was then manipulated using RasMol
v2.7.5 (Bernstein + Sons, Shirley New York).
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Table 5: The antibodies used for Western blots
Name

c-Myc (monoclonal)

GAPDH

Lamin A/C

Flotillin-1

Species Dilution Manufacturer

Mouse

Rabbit

Goat

Rabbit

1:4000

1:2000

1:500

1:500

Secondary Antibody

Cedarlane

Goat α-Mouse, linked to

(Burlington,

horseradish peroxidase

Ontario)

(titre: 1:5000) (Bio-Rad)

Abcam

Swine α-Rabbit linked to

(Toronto,

horseradish peroxidase

Ontario)

(titre: 1:2500) (DAKO)

Santa Cruz

Mouse α-Goat, linked to

(Dallas,

horseradish peroxidase

Texas)

(titre: 1:500) (Santa Cruz)

Abcam

Swine α-Rabbit linked to

(Toronto,

horseradish peroxidase

Ontario)

(titre: 1:2500) (DAKO)
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2.8.2 Identification of putative classical NLS
cNLS Mapper (http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi), an online
service for the detection of importin-α dependent nuclear localization signals was used to analyze
the PH domain of RGNEF for possible NLSs. cNLS mapper is based on the results of an activity
based profile for different importin-α dependent NLSs created by systematic amino acid
replacement analysis in budding yeast (97,124,125).

2.8.3 Statistical analysis
All statistical analyses, including bar graphs, were performed or generated using
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, California, USA).
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Chapter 3
3

Experimental results

3.1 Aim 1: Determine the effects of the PH domain on
subcellular localization of RGNEF
3.1.1 The PH domain of RGNEF has the molecular shape consistent with
PH domains
It was first necessary to confirm that the PH domain of RGNEF contained the 7 β-sandwich
structure with C-terminal α-helix characteristic of PH domains. Figure 9 shows a side by side
comparison of the N-terminal PH domain of Pleckstrin – the protein in which the PH domain
was first identified - next to the PH domain of RGNEF (amino acids 1082-1201). The PH
domain of RGNEF does show 7 β-sheets with a C-terminal α-helix. The β-sheets and the α-helix
are of approximately the same size and in the same orientation between the two models. This is
consistent with past findings in our lab that showed RGNEF acts as a GEF for RhoA as PH
domains are a necessary component of GEF activity (17,19)

3.1.2 The transfection efficiency is not significantly different between
RGNEF and RGNEF-ΔPH constructs in HEK293T cells
Transfection efficiency was determined by cell counting. Transfected HEK293T cells were
stained by ICC and the percentage of cells expressing the myc tagged construct was determined
by confocal microscopy. There was no significant difference in number of cells expressing
RGNEF-ΔPH from full length RGNEF (Fig. 10; 90% ± 3% vs 92% ± 2%, respectively; p =
0.438) as measured by a two-tailed independent sample T-test.
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3.1.3 RGNEF-∆PH shows differential localization to the nucleus
Both fractionation and ICC show RGNEF-∆PH was localized to the nucleus to a lower
proportion than full length RGNEF; though differential levels of localization to the plasma
membrane could not be

Figure 8: Comparison of the molecular structures of the N-terminal Pleckstrin and
RGNEF PH domains. Molecular modeling of the PH domains of Pleckstrin and RGNEF. The
PH domain of RGNEF shares the molecular shape used to define PH domains. This includes a 7
β-sandwich structure with a C-terminal α-helix. The model was created using I-Tasser
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (116–118) and manipulated using RasMol
v2.7.5 (Bernstein + Sons, Shirley New York). The amino acid sequence of Pleckstrin was
obtained from PubMed.
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Figure 10: The transfection efficiency of RGNEF and RGNEF-ΔPH constructs measured
by cell counting. The two construct show no significant difference (92% ± 2% vs 90% ± 3%,
RGNEF and RGNEF-ΔPH respectively; p = 0.438) in the percentage of cells expressing each
construct as measured by cell counting with confocal microscopy. Error bars show standard
deviation.
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confirmed. Transfected cells imaged by ICC confirm a reduced level of RGNEF-∆PH
recruitment to the nucleus with no apparent difference between constructs in membrane or
cytosolic localization (Fig. 11). Confocal images of neither construct show high levels of
recruitment to the plasma membrane. Cytosolic expression of both constructs appears diffuse.
Differential localization of either construct to the nucleus was quantified by manual counting
aided by intensity profiles generated by ZEN software (Carl Zeiss Canada; Fig. 12). RGNEF∆PH showed a significant decrease compared to RGNEF in the percentage of cells showing
nuclear localization of the construct (Fig. 13; 12% ± 5% vs 39% ± 8%, respectively; p = 0.014).

Subcellular fractionation of HEK293T cells transfected with either construct showed a lower
level of RGNEF-∆PH in nucleosolic fraction compared to cells transfected with RGNEF (Fig. 14
A & B). Nucleosolic fractions from RGNEF-ΔPH transfected HEK293T cells showed no α-myc
stained band at 180 kDa, suggesting RGNEF-ΔPH is completely absent from the nucleus.
Densitometry confirmed a significant reduction in nuclear localization of respective constructs in
RGNEF-∆PH compared to RGNEF transfected cells (0.3 ± 0.1 vs 2.1 ± 0.6, respectively; p =
0.009). No significant difference was shown in the cytosolic fractions (Fig. 14 C & D; 2.4 ± 0.1
vs 2.3 ± 0.4, respectively; p = 0.379). Membrane fractions showed an apparent decrease in
RGNEF-∆PH recruitment to membranes compared to RGNEF that was not observed in confocal
images (Fig 14E).
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Figure 11: The subcellular localization of RGNEF and RGNEF-ΔPH as demonstrated by confocal microscopy. The subcellular
localization in HEK293T cells as demonstrated by ICC with confocal microscopy. Panel A shows a high level of full length RGNEF
localized throughout the cell, including within the nucleus (Panels B and C). Panel D-F shows that RGNEF-ΔPH is absent from the
nucleus. Neither construct shows high levels of recruitment to the plasma membrane. Myc-tagged proteins were visualized using antimyc antibody and Alexa 488 secondary antibody (green). The nucleic acid was visualized using Hoechst (blue). Scale bar represent 15
μm.
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Figure 11: Intensity profiles generated using Zen Software of confocal images for RGNEF
and RGNEF-ΔPH. Profiles (Panels A and C) show intensity profiles generated using ZEN
software. Intensity (Y-Axis) is mapped against distance (X-Axis) across the cell, which is
indicated by the white bar in panels B and D. The intensity profile (Panel A) for RGNEF shows
consistently high levels of signal intensity of green channel (α-myc staining for our construct) as
levels of blue (Hoechst) increase. The intensity profile for RGNEF-ΔPH (Panels C) shows the
intensity of green drops off as blue increases. Myc-tagged proteins were visualized using antimyc antibody and Alexa 488 secondary antibody (green). The nucleic acid was visualized using
Hoechst (blue).
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Figure 13: Subcellular localization measured as the percentage of cells showing nuclear
localization of RGNEF and RGNEF-ΔPH as determined by cell counting. Manual cell
counting, aided by intensity profiles, was performed to determine average number of cells with
nuclear localization of the construct. HEK293T cells transfected with RGNEF-ΔPH showed
significantly lower levels of cells with construct nuclear localization than those transfected with
full length RGNEF (12% ± 5% vs 39% ± 8%, respectively; p = 0.014) as determined using a
two-tailed independent sample T-Test. Error bars show standard deviation.
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Figure 13: Subcellular localization measured by subcellular fraction with Western blot and densitometry. Fractionation of
HEK293T cells transfected with either construct show a reduced level of RGNEF-ΔPH recruited to the nucleus compared to RGNEF
(Panels A & B; 0.3 ± 0.1 vs 2.1 ± 0.6, respectively; p = 0.009). No significant difference was found between levels of RGNEF-ΔPH
and RGNEF in the cytosolic fractions (Panels C & D; 2.4 ± 0.1 vs 2.3 ± 0.4, respectively; p = 0.379). A two-tailed independent sample
T-test was used to determine significance. Low levels of the construct were shown in the membrane fraction of cells transfected with
RGNEF. This was absent in cells transfected with RGNEF-ΔPH, suggesting a lower level of RGNEF-ΔPH recruitment to the
membrane. Error bars show standard deviation.
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3.2 Aim 2: Use of in Silico techniques to determine the apparent
PH domain dependent mechanism of nuclear import of RGNEF
3.2.1 The analysis of the amino acid sequence of the PH domain using
cNLS Mapper shows a putative NLS
The online software cNLS Mapper was used to predict the location of a putative NLS based on
amino acid sequence. An NLS from residues 18 - 45 of the PH domain (residues 1100 – 1127 of
full RGNEF) was predicted. Figure 15 shows the location of the NLS. The basic residues of the
NLS are indicated by asterisks.

3.2.2 The molecular modeling of the NLS in the PH domain confirms that
the basic residues are accessible for binding
Predictions by cNLS mapper are based on the amino acid sequence of a protein (98, 125, 126).
Therefore, we used the molecular modeling software RasMol (Bernstein + Sons, Shirley New
York) to map the position of the NLS to our existing model of the PH domain of RGNEF
(Section 3.1.1). Figure 16 shows that the basic residues (yellow) of the NLS (red) are located on
the exterior of the protein suggesting they are accessible for interaction with the concave surface
of importin-α (96).

3.3 Aim 3: Confirm the functionality of the putative NLS in the
PH domain of RGNEF
3.3.1 Mutagenesis to remove the basic residues of the NLS does not affect
the molecular structure of RGNEF’s PH domain
The four basic residues of the NLS were mutated to create RGNEF-mNLS, a construct that does
not contain the basic residues necessary for binding to importin-α. In order to confirm that the
mutations – either arginine to alanine or lysine to alanine – did not affect the molecular shape of
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Figure 15: The location of the NLS predicted by cNLS mapper. The software cNLS predicted an NLS (highlighted green) from
residues 18 – 45 of the PH domain (green font; residues 1100 – 1127 of full RGNEF). The basic residues (asterisks above) are located
in two clusters separated by 16 residues.
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Figure 15: Molecular modeling of the NLS within the PH domain of RGNEF. Panels A & C and B & D show the same rotation
with one being a ribbon model (A & B) and the other being a space fill model (C & D). The NLS (red) is shown to be located on the
exterior of the PH domain with the basic residues (yellow).
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the PH domain the amino acid sequence was submitted to the online software I-Tasser (117-119)
and the model was oriented using RasMol. Figure 17A shows a side by side comparison of the
PH domain of wild-type RGNEF against the mutated PH domain of RGNEF-mNLS. Figure 17BE shows the model at the same various angles used in Figure 16. The PH domain of RGNEFmNLS retains the same structure as the wild-type PH domain including the relative location of
the NLS residues.

3.3.2 The expression efficiency of RGNEF-mNLS is not significantly
different from that of full length RGNEF or RGNEF-ΔPH
The transfection efficiency for RGNEF-mNLS was determined using cell counting and Western
blot. First, ICC and confocal microscopy was performed on transfected HEK293T cells because
a new microscope was used for Aim 3 – a Leica SP8 replaced the Zeiss LSM 510 META used in
Aim 1 - the percentage of cells expressing the construct was determined for RGNEF, RGNEFΔPH, and RGNEF-mNLS by cell counting. No significant difference in the percentage of cells
expressing the construct was found between the three constructs when compared by a one-way
ANOVA (Fig. 18A p = 0.091).

The overall expression was measured by lysing transfected HEK293T cells, running a Western
blot, and performing densitometry (Fig 18B & C). Expression was normalized against GAPDH
expression. No significant difference was found in protein levels between constructs when
compared by a one-way ANOVA (p = 0.5403).

3.3.3 RGNEF-mNLS shows significantly lower levels of nuclear localization
than full length RGNEF, consistent with RGNEF-ΔPH
Cells transfected with RGNEF-mNLS show significantly lower levels of localization to the
nucleus as measured by confocal microscopy and Western blot. Transfected HEK293T cells
were stained by ICC and confocal microscopy was performed. Figure 19 shows a comparison of
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Figure 17: Comparison of the molecular structures of the wild-type RGNEF and RGNEFmNLS PH domains. Panel A shows a side by side comparison of the PH domains of wild-type
(WT) RGNEF against RGNEF-mNLS. Both PH domains show the same folding and relative
location of the NLS. Panels B-E show rotations of the RGNEF-mNLS model.
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Figure 18: The transfection efficiency of RGNEF, RGNEF-ΔPH, and RGNEF-mNLS measured by cell counting and by
Western blot. Panel A shows the results of cell counting using confocal microscopy. Cell counting for RGNEF and RGNEF-ΔPH was
repeated from Aim 1 (Section 3.1.2). No significant difference was shown in percentage of cells between constructs when compared
by a one-way ANOVA (p = 0.091). Panels B & C show levels of expression as measured by Western blot with densitometry. Relative
protein amount was determined by comparing α-myc bands, which represent the expression of each construct, against GAPDH bands.
We observed no significant difference in the relative protein amount between constructs as compared by a one-way ANOVA (p =
0.5403).
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Figure 19: The subcellular localization of RGNEF, RGNEF-ΔPH, and RGNEF-mNLS shown by confocal microscopy.
HEK293T cells transfected with RGNEF (Panels A-D) shows localization of the construct to the nucleus. Co-localization analysis
(Panel D) shows co-localization of RGNEF (green) with Hoechst stain (blue) within the nucleus. RGNEF-ΔPH (Panels K-H) and
RGNEF-mNLS (Panels I-L) show no construct in the nucleus and co-localization analysis (Panels H & L) shows co-localization only
around the periphery of the nucleus. Myc-tagged proteins were visualized using anti-myc antibody and Alexa 488 secondary antibody
(green). The nucleic acid was visualized using Hoechst (blue). The scale bar represents 15 μm.
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the three constructs. Panels D, H, and L show co-localization analysis; the regions where both
green (myc tag) and blue (Hoechst stain) overlap are colored white. RGNEF shows some level of
localization to the nucleus as shown by spots of co-localization seen throughout the nucleus.
RGNEF-mNLS shows the same pattern of exclusion from the nucleus as RGNEF-ΔPH: colocalization is seen only along the periphery of the nucleus and not within. Co-localization at the
periphery of the outer nuclear envelope likely represents our constructs collecting along the
nuclear membrane possibly as an early step in nuclear import. Because they lack the basic
residues for interaction with importin-α, they remain localized at the outer nuclear membrane.

The number of cells with our construct product protein in the nucleus were counted. Intensity
profiles (Fig. 20) generated by LAS X software were used to examine the level of expression of
the construct in the nucleus. We observed a significant difference in percentage of cells showing
nuclear expression between constructs when compared by a one-way ANOVA (p < 0.001). A
post-hoc Newman-Keuls test showed a significant difference in percentage of cells showing
nuclear localization between HEK293T cells transfected with RGNEF (44%) and RGNEFmNLS (11%; p < 0.001).

In order to complement the results observed in HEK293T cells, the neuronal cell type SH-SY5Y
was transfected, ICC was performed and cells were imaged by confocal microscopy (Fig. 22). In
addition to α-myc (green) and DAPI (blue), β-Tubulin III (red) was used as a marker of neuronal
differentiation and to label the entirety of the cell. Subcellular localization of the constructs is
similar in SH-SY5Y cells as to what is seen in HEK293T cells with reduced levels of RGNEFΔPH or RGNEF-mNLS localized to the nucleus compared to RGNEF. Co-localization analysis
(Panels E, J, & O) demonstrated greater levels of nuclear localization of construct in those cells
transfected with full length RGNEF than those transfected with either RGNEF-ΔPH (Panels F-J)
or RGNEF-mNLS (Panels K-O), where co-localization was seen only around the periphery of
the nucleus. This allows us greater ability to generalize our results to spinal motor neurons and to
the ALS pathology. As well, because differentiated SH-SY5Y cells are neuron-like and have
withdrawn from the cell cycle (127), it indicates that the nuclear localization observed in
HEK293T cells is independent of cell cycle.
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Figure 20: Intensity profiles generated using LAS X Software for confocal images of RGNEF, RGNEF-ΔPH, and RGNEFmNLS. Profiles (Panels A, C, & E) show intensity profiles generated using LAS X software. Intensity (Y-Axis) is mapped against
distance (X-Axis) across the HEK293T cell, which is indicated by the white bar in panels B, D, & F. The intensity profile (Panel A)
for RGNEF shows consistently high levels of signal intensity of green channel (α-myc staining for our construct) as levels of blue
(Hoechst) increase. For both RGNEF-ΔPH and RGNEF-mNLS (Panels C & E) the intensity of green drops off as blue increases. Myctagged proteins were visualized using anti-myc antibody and Alexa 488 secondary antibody (green). The nucleic acid was visualized
using Hoechst (blue).
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Figure 21: Subcellular localization measured as a percentage of cells showing nuclear
localization of RGNEF, RGNEF-ΔPH, and RGNEF-mNLS. Manual cell counting aided by
computer generated intensity profiles was used to determined average number of cells showing
nuclear localization of respective constructs. A significant difference in percentage of cells
showing construct in the nucleus was found between constructs (p < 0.001). A post-hoc
Newman-Keuls test showed a significant difference in percentage of cells showing nuclear
localization between HEK293T cells transfected with RGNEF (44%) and RGNEF-mNLS (11%;
p < 0.001). A significant difference was also found between RGNEF and RGNEF-∆PH (10%; p
< 0.001). Error bars show standard deviation.
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Figure 22: Confocal images showing subcellular localization of RGNEF, RGNEF-ΔPH, and RGNEF-mNLS in SH-SY5Y cells.
High levels of nuclear localization of RGNEF were observed using confocal microscopy (Panels A-E) where as much lower levels of
were observed for both RGNEF-ΔPH (Panels F-J) and RGNEF-mNLS (Panels K-O). Co-localization analysis (Panel E) demonstrated
that RGNEF co-localized with DAPI stain within the nucleus. However, RGNEF-ΔPH (Panel J) and RGNEF-mNLS (Panel O) were
co-localized largely around the periphery of the nucleus and at much lower levels within the nucleus itself. Myc-tagged proteins were
visualized using anti-myc antibody and Alexa 488 secondary antibody (green). Beta Tubulin III was visualized using Beta Tubulin III
antibody with Alexa 546 secondary antibody (red). Nucleic acid was visualized using DAPI (blue). The scale bar represent 15 μm.

74
The localization of RGNEF-mNLS in HEK293T cells was also measured by subcellular
fractionation with Western blotting and densitometry (Fig. 23). For the nuclear fraction (Panels
A & B), the level of construct was measured against Lamin A/C staining. A significant
difference was found in relative protein levels in nuclear fractions between constructs (Panels A
& B; p = 0.003). A Newman-Keuls test showed a significant difference between relative protein
levels in cells transfected with RGNEF (x̅ = 2.1) and either RGNEF-∆PH (x̅ = 0.3; p < 0.01) or
RGNEF-mNLS (x̅ = 0.4; p < 0.01). No significant difference was shown between RGNEF-∆PH
and RGNEF-mNLS p > 0.05). Expression in the cytosolic fraction was measured against
GAPDH as an internal control. When comparing cytosolic fraction (Panel C & D), no significant
difference in relative protein levels was shown between constructs (p = 0.434). Error bars
represent standard deviations.

3.3.4 The expression of constructs of 40 kDa or less in HEK293T cells
shows differential localization of PH-40 kDa and mNLS-40 kDa
In order to isolate the effects of the NLS on protein localization, three GFP-tagged constructs
were created. The PH-40 kDa construct expressed only the wild-type PH domain (amino acids
1082 – 1201). The NLS-26 kDa construct expressed only the wild-type bipartite NLS sequence
(amino acids 1100 -1128). The mNLS-40 kDa construct expressed only the PH domain from the
NLS mutated (RGNEF-mNLS) template inclusive of point-mutations to eliminate importin-α
binding (amino acids 1082 – 1201; R1101A, K1103A, K1120A, K1123A).

Figure 24 shows confocal microscope data for these three constructs with eGFP-C1 vector
transfected HEK293T cells for reference (Fig. 24a). Cells transfected with the eGFP-C1 vector
show diffuse expression including nuclear expression. Cells transfected with NLS-26 kDa (Fig.
24b) showed diffuse expression, comparable to that observed with eGFP-C1 transfected cells.
Although we anticipated that this construct might preferentially localize to the nucleus, it is
likely that because of its low molecular weight (26 kDa) that it was able to freely diffuse into and
out of the nucleus, resulting in diffuse localization. It is also possible that by expressing only 27
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Figure 23: Subcellular localization measured by cellular fractionation with Western blot and densitometry. Densitometry
results (Panels A & C) for Western blots obtained from HEK293T transfected with RGNEF-mNLS were compared against data
obtained for nuclear fractionation of RGNEF and RGNEF-ΔPH described previously (Section 3.1.3). A significant difference was
found in relative protein levels in nuclear fractions between constructs (Panels A & B; p = 0.003). A Newman-Keuls test showed a
significant difference between relative protein levels in cells transfected with RGNEF (x̅ = 2.1) and either RGNEF-∆PH (x̅ = 0.3; p <
0.01) or RGNEF-mNLS (x̅ = 0.4; p < 0.01). No significant difference was shown between RGNEF-∆PH and RGNEF-mNLS p >
0.05). When comparing cytosolic fraction (Panel C & D), no significant difference in relative protein levels was shown between
constructs (p = 0.434). Error bars represent standard deviations.
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amino acids of the PH domain the resulting protein did not fold into the characteristic β-stranded
structure seen in the endogenous PH domain (Fig. 9). As illustrated in Figure 16, the folding of
the PH domain results in the basic residues of the NLS (yellow) collecting along the exterior of
the domain. In the absence of the remainder of the PH domain it is possible that either the basic
residues do not collect near one another or that they are subject to steric interference from the
GFP-tag.

When transfected with the PH-40 kDa construct, HEK293T cells showed a variable pattern of
protein localization. Figure 24c shows some level of construct recruitment to the nucleus in all
cells at all levels of expression of the protein in the cell. Both cell 1 and cell 2 (as labelled in
figure) show high expression of the construct. However cell 2 shows high levels of construct
localized to the nucleus whereas cell 1 shows lower levels of expression in the nucleus. Cells 3
and 4 show moderate levels of construct expression although cell 3 shows nearly diffuse
expression of the construct through the nucleus and cell 4 shows much lower level of nuclear
expression. No cells showed higher levels of construct in the nucleus than in the cytoplasm. This
suggests that NLS function may be regulated by some form of post-translational modification
similar to the phosphorylation and methylation found in EWS and TAF15, respectively (73,76);
cells showing high levels of construct nuclear localization may contain the NLS in an active
state.

Figure 24d shows the expression of mNLS-40 kDa in HEK293T cells. As with PH-40 kDa, all
transfected cells show some level of protein in the nucleus. The levels of construct in the nucleus
appears lower than for PH-40 kDa, however no cell shows levels of nuclear expression as low as
what was seen previously with RGNEF-ΔPH (see Figure 11).

Despite the support for our hypothesis that these low molecular weight constructs add, it is
difficult to draw conclusive evidence from this data given that the literature offers three different
thresholds for nuclear diffusion: 40 kDa (84,85), 60 kDa (86–88), and as high as 110 kDa (89).
For example, cells transfected with PH-40 kDa or mNLS-40 kDa always showed some low level

78

79
Figure 24: The subcellular localization of constructs of 40 kDa or less as shown by confocal microscopy. Examination of the
subcellular localization by ICC and confocal microscopy shows diffuse expression of construct in eGFP-C1 (Panels A-C) and NLS-26
kDa (Panels D-F) transfected HEK293T cells. Cells transfected with PH-40 kDa (Panels G-I) show variable localization. Cell 1 & 2
(as indicated by label in figure) show high level of construct expression. Cell 1, however, shows much lower level of nuclear
expression. Cells 3 & 4 show lower level of protein expression with cell 4 showing lower levels of nuclear expression. HEK293T cells
transfected with mNLS-40 kDa (panels J-L) show lower levels of construct recruitment to the nucleus, though none as low as what
was seen previously with RGNEF-ΔPH. In all panels, green represents fluorescence by N-terminal GFP-tag. The nucleic acid was
visualized using Hoechst (blue). The scale bar represents 15 μm
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of construct in the nucleus, suggesting that low levels of the constructs were diffusing into the
nucleus. For this reason, we created constructs expressing proteins greater than the maximum
threshold for nuclear diffusion.

3.3.5 The expression of 160 kDa constructs in HEK293T cells shows
differential localization of PH-40 kDa and mNLS-40 kDa at levels equivalent
to full length constructs
The expression of mNLS-40 kDa (see Section 3.3.4) exhibited lower nuclear expression than
PH-40 kDa, though no cells showed levels as low as what had been previously seen in RGNEFΔPH or RGNEF-mNLS constructs. Therefore, we hypothesized that the nuclear localization of
constructs seen was due to passive diffusion of the construct into the nucleus. Therefore, we
created similar GFP-tagged constructs with the addition of the protein LacZ. This resulted in
constructs of approximately 160 kDa. These constructs (PH-160 kDa and mNLS-160 kDa) far
exceed the highest threshold estimate of 110 kDa for passive diffusion into the nucleus and
therefore should not be able to diffuse.

Figure 25 shows confocal images of HEK293T cells transfected with these constructs. Panel A
shows expression of only the pHM830 plasmid. This vector alone expresses the LacZ protein
with N-terminal GFP-tag. The protein is absent from the nucleus, indicating that LacZ+GFP
alone is sufficiently large enough to be excluded from the nucleus. Panel D shows high levels of
nuclear localization of PH-160 kDa, comparable to levels of full length RGNEF (Figures 19, 22)
and of PH-40 kDa (Figure 24). Panel G shows very low levels of nuclear localization of mNLS160 kDa, comparable to levels of RGNEF-ΔPH and RGNEF-mNLS (Figures 19, 22).

81

Figure 25: The subcellular localization of 160 kDa constructs as shown by confocal microscopy. Examination of subcellular
localization by ICC and confocal microscopy shows cytoplasmic localization only of the pHM830 vector, which expresses GFPtagged LacZ (Panel A-C). Panels D-F shows PH-160 kDa present in the nucleus. Panels G-I shows an absence of mNLS-160 kDa in
the nucleus, comparable to what is seen in pHM830 transfected cells. In all panels Green channel represents florescence by GFP tag
and blue represent florescence by Hoechst stain. The scale bar represents 15 μm.
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Chapter 4
4

Discussion

Here we report multiple lines of evidence supporting the presence of a NLS within the PH
domain of RGNEF. The interaction between cargo proteins and importin-α is facilitated by basic
residues within NLSs (94). Point-mutations of the basic residues of our identified NLS reduced
nuclear localization in both full-length constructs (RGNEF-mNLS) and in constructs expressing
only the PH domain (mNLS-160 kDa). Molecular modeling confirms that these mutations did
not change the overall molecular shape of the PH domain (Fig. 17). Our two lines of constructs,
full length constructs and isolated PH domain constructs, complement one another well in that
they confirm that NLS function also occurs in the full-length protein and that it functions
independently of other regions of the protein. As well, our use of the neuron-like SH-SY5Y cell
line to supplement data found in HEK293T cells allows us greater ability to generalize our
findings towards our understanding of ALS pathology.

4.1 Implications for our understanding of RGNEF function
Our data presented here, particularly our identified NLS, offers significant insight into the
function of RGNEF. It may also offer insight into the mechanism by which RGNEF destabilizes
NEFL mRNA (19,22). The mechanism by which RGNEF destabilizes NEFL mRNA likely
involves shuttling the mRNA species to a RNAse or complex in the cytoplasm to promote its
degradation. Having shown the mechanism by which RGNEF is able to localize to the nucleus, it
remains to be revealed whether RGNEF binds NEFL mRNA – or other target mRNA species –
within the nucleus and may contribute to their nuclear export.

The protective effect of RGNEF on cellular stress is likely not due to its nuclear import. Our lab
has previously shown that when transfected with full length RGNEF, HEK293T cells showed a
significantly greater percentage of cell survival when exposed to oxidative stress than those cells
which were transfected with empty vector. Cells transfected with constructs lacking the GEF
region (both DH and PH domains) showed a significant increase in survival over cells
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transfected with empty vector, suggesting that RGNEF’s nuclear localization is not necessary for
its function in stress protection (123).

It is of interest that regardless of the construct (full length RGNEF, RGNEF-ΔPH, or RGNEFmNLS) or the cell type (HEK293T (Fig. 19) or SH-SY5Y (Fig. 22)) we observed a prominent
localization of the construct at the nuclear membrane. We interpret this as our constructs
collecting at the outer nuclear membrane as an initial step prior to nuclear import. This may
implicate a second domain of RGNEF, the C-terminal microtubule binding domain (Fig. 4), as a
contributor to nuclear import. The microtubule cytoskeleton has been shown to contribute to the
nuclear import of parathyroid hormone-related protein (PTHrP), p53, retinoblastoma protein, and
Signal transducer and activator of transcription 5 (STAT5) (130,131). It is thought that binding
to microtubules facilitates transport through the cytoplasm to the nuclear envelope, where
nuclear import is then carried out by conventional means (binding karyopherins). Whether the
microtubule binding domain of RGNEF contributes to its transport to the nuclear envelope
remains to be determined.

Our data also suggests that RGNEF nuclear localization undergoes some form of regulation.
Figure 25 shows variable levels of nuclear localization between cells transfects with PH-160
kDa. Post-translational modifications of EWS and TAF15 have been shown to regulate their
nuclear localization (73,76). Phosphorylation sites along RGNEF, including within the PH
domain have previously been identified (132). Regulation of NLS activity likely occurs within
the PH domain as the constructs in which we found differential localization between cells (PH40 kDa, and PH-160 kDa) expressed only the PH domains of RGNEF. Regulation of RGNEF
may contribute to its role in disease pathology.

4.2 Implications for our understanding of ALS pathology
The role of RGNEF in ALS pathology is currently unknown. It has been shown to destabilize
NEFL mRNA (19), which encodes the NF subunit NFL. Stoichiometric balance of the NF
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subunits and of NFL in particular is critical to the formation of the NCIs seen in ALS motor
neurons (133). Like RGNEF, TDP-43 also acts as a stability factor for NEFL mRNA (39), forms
ubiquitinated inclusions in ALS patients (48), and contains an NLS, allowing it to localize to the
nucleus (53). Because TDP-43 acts to stabilize NEFL mRNA and RGNEF acts to destabilize
NEFL mRNA, it is possible that together these two represent a feedback system that acts to
maintain NFL expression levels. The ALS-specific mutations identified in ARHGEF28 result in
severely truncated proteins, which do not express either the RNA binding domain or the NLScontaining PH domain (20,121,122). It is possible that the loss of RGNEF as a regulator of
NEFL mRNA increases susceptibility for ALS. As well, it is possible that the dysregulation of
nuclear transport proteins – including importin-α, RCC1, and RanGAP – observed in cells
expressing C9orf72 expanded repeats (7) may result is the mislocalization of RGNEF and TDP43, again resulting in the dysregulation of NEFL mRNA.

Measuring the localization of endogenously expressing RGNEF – rather than transient
expression of artificial constructs – is critical to our understanding of its role in healthy cells. Our
current study proved the capacity for RGNEF to undergo nuclear import in transiently
transfected cells. Elucidating the endogenous localization of RGNEF in healthy and ALS motor
neurons will help further our understanding of RGNEF’s role in motor neuron degeneration.

4.3 Implications for our understanding of PH domains
Of note is our novel finding of a PH domain-embedded NLS. Though PH domains are the
eleventh most common domain in the human genome (17), to date none have been reported to
contain an NLS. Because importin-α binding by NLSs (94) and PtdIns (17) binding by PH
domains is facilitated by basic residues, it is reasonable to believe that they occur in tandem
more frequently than what has been found in the literature. One potential reason for under
reporting NLSs within PH domains may be due to the highly conserved folding present in PH
domains. Domain prediction software that does not take into consideration the molecular folding
could easily yield false positive or false negatives in predicting NLSs. Notice in Figure 16 how
the basic residues of the NLS are located on the edges of the β-sheets, which form the β-
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sandwiches. This locates the residues on the exterior of the domain (Fig. 16) and reduces the
probability of steric interference. Predictive software may falsely predict an NLS composed of
basic residues within the β-sandwich, where they are inaccessible for interaction. As well,
software using the classical definition of bipartite NLSs, which set the maximum length of the
linker region between basic clusters at 12 residues, may fail to predict NLS. Work done in 2010
has since proven that the linker region may be as long as 29 residues (95). Software using this
classical definition would fail to predict an NLS in a PH domain as the length of the β-sheets is
fairly well conserved at around 16 residues (Fig. 9) meaning the software would not accurately
predict residues located on the exterior of the molecule.

Table 6 shows the results derived from analysis using cNLS Mapper (http://nlsmapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) for 15 other PH domain-containing
proteins. For reference, RGNEF is shown along the top and in italics. Proteins are sorted in
descending ordered based on estimate molecular weight. Amino acids sequences for all proteins
were obtained from PubMed. Accession numbers for all proteins are available in Appendix B. A
score is assigned by cNLS mapper to predict the localization of the protein. Scores between three
to five are predict that the protein will spend equal amounts of time in both the nucleus and
cytoplasm. Scores above five indicate the protein is predicted to spend more time in the nucleus
than the cytoplasm. Scores below three indicate the protein is predicted to spend more time in the
cytoplasm than the nucleus (97,124,125). A putative bipartite NLS was identified in every PH
domain analyzed using cNLS mapper and many identified obtained a score about three. Of note
are proteins like Spectrin β 2 (134), Phospholipase C β (135), and Burton's tyrosine kinase
(BTK) (136), which have previously been shown in the literature to localize to the nucleus
despite their large molecular weight. For example, BTK is reported to localize predominantly to
the cytoplasm but has also been observed within the nucleus (136). The mechanism by which
BTK undergoes nucleus localization has not been identified (137). Work done in 2000
investigated a putative NLS within the PH domain of BTK and concluded that it was not
responsible for nuclear import. However, it is worth noting that the techniques used in this work
were not as sensitive as what we have outlined here. In particular, the only construct used to
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Table 6: Results of analysis using cNLS Mapper on other PH domain-containing proteins

Protein Name

Score by
cNLS
Mapper

Length
(AA)

Molecular
Weight*
(kDa)

RGNEF

4.4

1731

190.4

GRFKDILALLLTDVLLFLQEKDQKYIFA

Spectrin β 2

5.2

2390

262.9

EAFGKKAANRSWQNVYCVLRRGSLGFYKDAKA

Phospholipase C γ

3.1

1290

141.9

EIRPGKTSRDFDRYQEDPAFRPDQSHCFVILY

Phospholipase C β

3.1

1181

129.9

RFGKFAKMPKSQKLRDVFNMDFPDNSFLLKTLT

Dynamin-1

4.9

851

93.61

KGGSKEYWFVLTAENLSWYKDDEEKEKKYMLS

Phospholipase C δ

3.9

756

83.1

ESRKVMRTPESQLFSIEDIQEVRMGHRTEG

Burton's tyrosine kinase (BTK)

4.2

693

76.2

NFKKRLFLLTVHKLSYYEYDFERGRRGSK

beta adrenergic receptor kinase

4.7

689

75.7

RKCLLLKIRGGKQFILQCDSDPELVQWKKELRD

Tyrosine-protein kinase (TSK)

5.3

620

68.2

RRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLK

556

61.1

RKGLFARRRQLLLTEGPHLYYVDPVNKVLKGE

480

52.8

FIGYKERPQDVDQREAPLNNFSVAQCQLMKTE

425

46.7

KQKPKTPFCFVINALSQRYFLQANDQKDMKDW

3-phosphoinositide-dependent protein
5.6
kinase
RAC-alpha serine/threonine-protein
2.9
kinase
Pleckstrin homology domain-containing
family A member 2 [N-Terminal PH
5.7
domain]
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Pleckstrin homology domain-containing
family A member 2 [C-Terminal PH
4.2
domain]

425

46.7

RKSWKRRFFALDDFTICYFKCEQDREPLRTI

Arno protein

4.2

399

43.8

RVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIP

Pleckstrin [N-Terminal PH domain]

4.4

350

38.5

ITTTKQQDHFFQAAFLEERDAWVRDIKKAI

Pleckstrin [C-Terminal PH domain]

2.1

350

38.5

RRKNWKVRKFILREDPAYLHYYDPAGAEDPLGAIH

Pleckstrin homology domain-containing
3.6
family A member 3

300

33

DAPP1 protein

280

30.8

2.8

EIKVHSADNTRMELIIPGEQHFYMKAVNA
EGYLTKQGGLVKTWKTRWFTLHRNELKYFKD

* Molecular weight for each protein was estimated based on number of amino acids using the formula
number of amino acids X 110 dalton/amino acids = Molecular weight in dalton
Higher scores indicate stronger NLS activities. A score of 8, 9, or 10 is exclusively localized to the nucleus, a score
of 7 or 8 partially localized to the nucleus, a score of 3, 4, or 5 localized to both the nucleus and the cytoplasm , and a
score of 1 or 2 localized to the cytoplasm.
Values between three to five are highlighted in green. Values below three are highlighted in blue.
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analyze the putative NLS involved the deletion of not only the entire PH domain but also the
adjacent tec homology (TH) domain: a loss of about 200 amino acids or an estimated 22kDa
(138). It is possible that this differential in molecular weight may have confounded their analysis
of nuclear localization. As well, this large deletion may have affected molecular folding of the
protein. We hypothesize that were we to use site directed mutagenesis to mutate only those basic
residues likely to be involved in nuclear import we would be able to show differential nuclear
localization. Figure 26 shows the location of the NLS which we have identified using cNLS
mapper. Like for RGNEF, the model of the PH domain of BTK shows the basic residues collect
along the exterior of the domain, suggesting they would be available for interaction with
importin-α.

Given the evidence our analysis of 15 PH domain-containing proteins and our specific
elucidation of the PH domain of RGNEF has yielded, it is likely that the number of PH domainembedded NLS is underrepresented in the literature. The techniques outlined here should be used
in future work to further validate this hypothesis.
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Figure 26 The location of the putative NLS in BTK. Panels A & C and B & D show the same
rotation with one being a ribbon model (A & B) and the other being a space fill model (C & D).
The NLS (red) is shown to be located on the exterior of the PH domain with the basic residues
(yellow). Panel E shows the location of the NLS within the amino acid sequence. The PH
domain is shown in green font. The putative NLS is highlighted in green. The basic residues of
the NLS are marked by asterisks above.
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Appendices

Appendix A: Optical Settings for Confocal Microscopy. The diagram illustrates the principles
of confocal microscopy. Light generated by the laser is filtered by a main dichroic beam splitter
and focused on the sample. When excited by specific wavelengths, fluorophores in the sample
emit light. The light produced by this excitation is passed through a second dichroic beam splitter
and is absorbed by a detector. The laser wavelengths, and main & secondary beam splitters used
for each fluorophore are listed here.
BP = Band Pass Filter; DD = Double dichroic; LP = Low Pass Filter
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Appendix B: Data obtained from PubMed for analysis using cNLS Mapper on other PH domain-containing proteins

Name
Spectrin beta chain,
non-erythrocytic 2
[Homo sapiens]
Phospholipase Cgamma [Homo
sapiens]
Phospholipase Cbeta-2 [Homo
sapiens]
Dynamin-1 [Homo
Sapiens]
Phospholipase c
delta 1 [Homo
sapiens]
Tyrosine-protein
kinase BTK isoform
3 [Homo sapiens]
Beta adrenergic
receptor kinase
[Homo Sapiens]
TSK / ITK tyrosineprotein kinase
[Homo Sapiens]
(PDK1) 3phosphoinositidedependent protein

Location
Access of PH
-ion
domain
Numb- (Amino
er
Acids)

Amino Acid Sequence of PH Domain

NP_00
8877

2221..232
4

MEGMLCRKQEMEAFGKKAANRSWQNVYCVLRRGSLGFYKDAKAASAGVPYHGEVPVSLAR
AQGSVAFDYRKRKHVFKLGLQDGKEYLFQAKDEAEMSSWLRVVN

AAA3
6452

29..151

LEVGTVMTLFYSKKSQRPERKTFQVKLETRQITWSRGADKIEGAIDIREIKEIRPGKTSRDFDRY
QEDPAFRPDQSHCFVILYGMEFRLKTLSLQATSEDEVNMWIKGLTWLMEDTLQAPTPL

AAA3
6453

17..144

LSQGERFIKWDDETTVASPVILRVDPKGYYLYWTYQSKEMEFLDITSIRDTRFGKFAKMPKSQ
KLRDVFNMDFPDNSFLLKTLTVVSGPDMVDLTFHNFVSYKENVGKAWAEDVLALVKHPLTA
NASR

AAH5
0279

520..623

VIRKGWLTINNIGIMKGGSKEYWFVLTAENLSWYKDDEEKEKKYMLSVDNLKLRDVEKGFM
SSKHIFALFNTEQRNVYKDYRQLELACETQEEVDSWKASFLRA

AAA7
3567

22..139

LLKGSQLLKVKSSSWRRERFYKLQEDCKTIWQESRKVMRTPESQLFSIEDIQEVRMGHRTEGL
EKFARDVPEDRCFSIVFKDQRNTLDLIAPSPADAQHWVLGLHKIIHHSGSMDQRQ

NP_00
12742
73

40..200

LESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRGSKKGSIDVEKITCVETVVP
EKNPPPERQIPRRGEESSEMEQISIIERFPYPFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYN
SDLVQKYHPCFWIDGQYLCCSQTAKNAMGCQ

CAA4
3470

553..670

YALGKDCIMHGYMSKMGNPFLTQWQRRYFYLFPNRLEWRGEGEAPQSLLTMEEIQSVEETQI
KERKCLLLKIRGGKQFILQCDSDPELVQWKKELRDAYREAQQLVQRVPKMKNKPRS

NP_00
5537

7..148

LEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISI
PCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRC
CSQLEKLATGCAQYDP

NP_00
2604

441..547

KQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWS
QELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRY
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kinase 1 isoform 1
[Homo sapiens]
RAC-alpha
serine/threonineprotein kinase
[Homo sapiens]
Pleckstrin homology
domain-containing
family A member 2
[Homo Sapiens] - NTerminal
Pleckstrin homology
domain-containing
family A member 2
[Homo Sapiens] - CTerminal
Arno protein (ARF
exchange factor)
[Homo sapiens]
Pleckstrin [Homo
sapiens] - N terminal
Pleckstrin [Homo
sapiens] - CTerminal
Pleckstrin homology
domain-containing
family A member 3
[Homo sapiens]
DAPP1 protein
[Homo sapiens]

NP_00
10144
32

4..111

VAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKT
ERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLK

NP_06
7636

1..119

MPYVDRQNRICGFLDIEEHENSGKFLRRYFILDTQANCLLWYMDNPQNLAMGAGAVGALQL
TYISKVSIATPKQKPKTPFCFVINALSQRYFLQANDQKDMKDWVEALNQASKITVPKG

NP_06
7636

199..297

LIKSGYCVKQGNVRKSWKRRFFALDDFTICYFKCEQDREPLRTIFLKDVLKTHECLVKSGDLL
MRDNLFEIITSSRTFYVQADSPEDMHSWIKEIGAAV

CAA6
8084

262..375

REGWLLKLGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVDDPRKPNCFELY
IPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAAVS

NP_00
2655

3..110

PKRIREGYLVKKGSVFNTWKPMWVVLLEDGIEFYKKKSDNSPKGMIPLKGSTLTSPCQDFGKR
MFVFKITTTKQQDHFFQAAFLEERDAWVRDIKKAIKCIEGGQKFA

NP_00
2655

239..346

EEFRGVIIKQGCLLKQGHRRKNWKVRKFILREDPAYLHYYDPAGAEDPLGAIHLRGCVVTSVE
SNSNGRKSEEENLFEIITADEVHYFLQAATPKERTEWIRAIQMAS

NP_06
1964

1..100

MEGVLYKWTNYLTGWQPRWFVLDNGILSYYDSQDDVCKGSKGSIKMAVCEIKVHSADNTR
MELIIPGEQHFYMKAVNAAERQRWLVALGSSKACLTDTRT

AAH1
2924

163..258

SLGTKEGYLTKQGGLVKTWKTRWFTLHRNELKYFKDQMSPEPIRILDLTECSAVQFDYSQER
VNCFCLVFPFRTFYLCAKTGVEADEWIKILRWKL
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